UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended ~~June 30, 2019~~March 31, 2020

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______ to ______

Commission file number: 001-37717

Senseonics Holdings, Inc.

(Exact name of registrant as specified in its charter)


Delaware (State or other jurisdiction of incorporation or organization)	3841 (Primary Standard Industrial Classification Code Number)	47‑1210911 (I.R.S. Employer Identification Number)

20451 Seneca Meadows Parkway

Germantown, MD 20876‑7005

(301) 515‑7260

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value	SENS	NYSE American

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days Yes ☒No ◻

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒No ◻

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer	◻	Accelerated filer	☒
Non-accelerated filer	◻	Smaller reporting company	☒
Emerging growth company	☒◻		

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

There were ~~203,168,205~~227,641,604 shares of common stock, par value $0.001, outstanding as of ~~August 6, 2019.~~June 5, 2020.

Table of Contents

TABLE OF CONTENTS

PART I: Financial Information

ITEM 1: Financial Statements

Condensed Consolidated Balance Sheets as of ~~June 30, 2019~~March 31, 2020 (Unaudited) and December 31, ~~2018~~2019	23
Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for three ~~and six~~ months ended ~~June 30,~~March 31, 2020 and 2019 ~~and 2018~~	34
Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit) for the three ~~and six~~ months ended ~~June 30,~~March 31, 2020 and 2019 ~~and 2018~~	45
Unaudited Condensed Consolidated Statements of Cash Flows for the ~~six~~three months ended ~~June 30,~~March 31, 2020 and 2019 ~~and 2018~~	56
Notes to Unaudited Condensed Consolidated Financial Statements	67

ITEM 2: Management Discussion and Analysis of Financial Condition and Results of Operations	2322

ITEM 3: Quantitative and Qualitative Disclosures about Market Risk	3635

ITEM 4: Controls and Procedures	36

PART II: Other Information	36

ITEM 1: Legal Proceedings	3736

ITEM 1A: Risk Factors	3736

ITEM 2: Unregistered Sales of Equity and Securities and Use of Proceeds	3840

ITEM 3: Defaults Upon Senior Securities	3940

ITEM 4: Mine Safety Disclosures	3940

ITEM 5: Other Information	3940

ITEM 6: Exhibits	3941

SIGNATURES	4142

Table of Contents

Explanatory Note

Senseonics Holdings, Inc. (the “Company”) relied on the Securities and Exchange Commission’s Order under Section 36 of the Securities Exchange Act of 1934, as amended, Modifying Exemptions from the Reporting and Proxy Delivery Requirements for Public Companies dated March 25, 2020 (Release No. 34-88465) (the “Order”) to delay the filing of its quarterly report on Form 10-Q for the quarter ended March 31, 2020 (the “Form 10-Q”) due to circumstances related to the coronavirus disease (“COVID-19”).

The Company’s operations and business have experienced disruption due to the unprecedented conditions surrounding the COVID-19 pandemic. The state of Maryland, where the Company is headquartered, has been affected by COVID-19. The Governor of Maryland has issued an order closing all non-essential businesses, which took effect on March 23, 2020. Substantially all of the Company’s workforce is currently working from home either all or substantially all of the time, including the Company’s limited number of general administrative and finance personnel. These safety measures have restricted access to the Company’s facilities and records, and have disrupted routine interactions among the Company’s staff, advisors and third parties involved in the preparation of the Form 10-Q.

In addition, the Company’s personnel who are primarily responsible for preparing its Form 10-Q have been mobilized on key business continuity efforts that have emerged in part as a result of COVID-19, including financing activities and cost-reduction initiates (including significant headcount reductions), following the Company’s payment of all amounts outstanding under its loan and security agreement with Solar Capital Ltd. on March 22, 2020. These factors resulted in a delay in the Company’s ability to complete its quarterly review processes in time to file the Form 10-Q by May 11, 2020. The Company is filing the Form 10-Q within 45 days after the standard filing deadline as permitted by the Order.

Table of Contents

Senseonics Holdings, Inc.

Condensed Consolidated Balance Sheets

(in thousands, except share and per share data)


	June 30,		December 31,		March 31,		December 31,
	2019		2018		2020		2019

	(unaudited)					(unaudited)
Assets
Current assets:
Cash and cash equivalents	$	65,296	$	136,793	$	18,605	$	95,938
Accounts receivable		839		830
Restricted cash						200		—
Accounts receivable, net						991		3,239
Accounts receivable - related parties		4,963		6,267		5		7,140
Inventory, net		16,787		10,231		4,995		16,929
Prepaid expenses and other current assets		6,091		3,985		5,740		4,512
Total current assets		93,976		158,106		30,536		127,758

Deposits and other assets		2,142		117		2,930		3,042
Property and equipment, net		2,278		1,750		1,803		2,001
Total assets	$	98,396	$	159,973	$	35,269	$	132,801

Liabilities and Stockholders’ Equity
Liabilities and Stockholders’ Deficit
Current liabilities:
Accounts payable	$	4,779	$	4,407	$	2,490	$	4,285
Accrued expenses and other current liabilities		16,922		13,851		15,371		18,636
Deferred revenue		—		628
Term Loans, accrued interest		2,002		—
Term Loans, current portion		9,901		10,000
Term Loans, net of discount						—		43,434
2025 Notes, net of discount						—		60,353
Total current liabilities		33,604		28,886		17,861		126,708

Term Loans, net of discount and current portion		—		4,783
2023 Notes, net of discount		37,815		36,103		12,412		12,464
Derivative liability		10,130		17,091
Term Loans, accrued interest		—		1,764
2025 Notes, net of discount						51,868		—
Other liabilities		1,674		85		2,089		2,278
Total liabilities		83,223		88,712		84,230		141,450

Commitments and contingencies (Note 8)
Commitments and contingencies

Stockholders’ equity:
Common stock, $0.001 par value per share; 450,000,000 shares authorized; 177,031,842 and 176,918,381 shares issued and outstanding as of June 30, 2019 and December 31, 2018		177		177
Stockholders’ deficit:
Common stock, $0.001 par value per share; 450,000,000 shares authorized; 204,444,835 and 203,452,812 shares issued and outstanding as of March 31, 2020 and December 31, 2019						204		203
Additional paid-in capital		433,229		428,878		466,771		464,491
Accumulated deficit		(418,233)		(357,794)		(515,936)		(473,343)
Total stockholders' equity		15,173		71,261
Total liabilities and stockholders’ equity	$	98,396	$	159,973
Total stockholders' deficit						(48,961)		(8,649)
Total liabilities and stockholders’ deficit					$	35,269	$	132,801

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

Senseonics Holdings, Inc.

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share data)


	Three Months Ended				Six Months Ended				Three Months Ended
	June 30,				June 30,				March 31,
	2019		2018		2019		2018		2020		2019
Revenue, net	$	1,475	$	553	$	2,718	$	931	$	31	$	1,243
Revenue, net - related parties		3,132		3,070		5,312		5,638		5		2,180
Total revenue										36		3,423
Cost of sales		9,160		3,839		15,893		7,147		19,670		6,733
Gross profit		(4,553)		(216)		(7,863)		(578)		(19,634)		(3,310)

Expenses:
Sales and marketing expenses		14,179		6,177		27,013		9,618		11,145		12,834
Research and development expenses		10,504		8,289		17,612		16,402		7,362		7,108
General and administrative expenses		5,417		5,382		11,933		9,393		5,690		6,516
Operating loss		(34,653)		(20,064)		(64,421)		(35,991)		(43,831)		(29,768)
Other income (expense), net:
Other income, net:
Interest income		410		241		1,037		425		209		627
Loss on extinguishment of debt										(4,546)		—
Interest expense		(1,965)		(2,236)		(3,999)		(4,007)		(4,373)		(2,034)
Change in fair value of derivative liability		4,889		(10,166)		6,961		(15,013)
Other income (expense)		245		(271)		(17)		(183)
Total other income (expense), net		3,579		(12,432)		3,982		(18,778)
Change in fair value of derivative liabilities										10,311		2,072
Other expense										(363)		(262)
Total other income, net										1,238		403

Net loss		(31,074)		(32,496)		(60,439)		(54,769)		(42,593)		(29,365)
Total comprehensive loss	$	(31,074)	$	(32,496)	$	(60,439)	$	(54,769)	$	(42,593)	$	(29,365)

Basic and diluted net loss per common share	$	(0.17)	$	(0.23)	$	(0.34)	$	(0.40)	$	(0.21)	$	(0.17)
Basic and diluted weighted-average shares outstanding		177,012,497		138,767,873		176,983,467		137,923,135		203,745,974		176,954,116

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

Senseonics Holdings, Inc.

Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit)

(in thousands)


				Additional				Total					Additional				Total
	Common Stock			Paid-In		Accumulated		Stockholders'		Common Stock			Paid-In		Accumulated		Stockholders'
	Shares	Amount		Capital		Deficit		Equity (Deficit)		Shares	Amount		Capital		Deficit		Equity (Deficit)
Three months ended June 30, 2018:
Balance, March 31, 2018	137,240	$	137	$	272,787	$	(286,096)	$	(13,172)
Issued shares of common stock	37,341		38		149,058		—		149,096
Exercise of stock options for cash and warrants	900		1		433		—		434
Conversion of 2023 Notes	735		1		249		—		250
Stock-based compensation expense and vesting of RSUs	26		—		1,603		—		1,603
Net loss	—		—		—		(32,496)		(32,496)
Balance, June 30, 2018	176,242	$	177	$	424,130	$	(318,592)	$	105,715

Six months ended June 30, 2018:
Balance, December 31, 2017	136,883	$	137	$	270,953	$	(263,823)	$	7,267
Issued shares of common stock	37,341		38		149,058		—		149,096
Exercise of stock options and warrants	1,212		1		813		—		814
Conversion of 2023 Notes	735		1		249		—		250
Stock-based compensation expense and vesting of RSUs	71		—		3,057		—		3,057
Net loss	—		—		—		(54,769)		(54,769)
Balance, June 30, 2018	176,242	$	177	$	424,130	$	(318,592)	$	105,715

Three months ended June 30, 2019:
Balance, March 31, 2019	176,958	$	177	$	430,926	$	(387,159)	$	43,944
Balance, December 31, 2018										176,918	$	177	$	428,878	$	(357,794)	$	71,261
Exercise of stock options for cash and warrants	36		—		71		—		71	15		—		23		—		23
Stock-based compensation expense and vesting of RSUs	37		—		2,232		—		2,232	25		—		2,025		—		2,025
Net loss	—		—		—		(31,074)		(31,074)	—		—		—		(29,365)		(29,365)
Balance, June 30, 2019	177,031	$	177	$	433,229	$	(418,233)	$	15,173
Balance, March 31, 2019										176,958	$	177	$	430,926	$	(387,159)	$	43,944

Six months ended June 30, 2019:
Balance, December 31, 2018	176,918	$	177	$	428,878	$	(357,794)	$	71,261
Exercise of stock options	51		—		94		—		94

Balance, December 31, 2019										203,453	$	203	$	464,491	$	(473,343)	$	(8,649)
Issued shares of common stock										175		—		(86)		—		(86)
Exercise of stock options and warrants										754		1		497		—		498
Stock-based compensation expense and vesting of RSUs	62		—		4,257		—		4,257	63		—		1,869		—		1,869
Net loss	—		—		—		(60,439)		(60,439)	—		—		—		(42,593)		(42,593)
Balance, June 30, 2019	177,031	$	177	$	433,229	$	(418,233)	$	15,173

Balance, March 31, 2020										204,445	$	204	$	466,771	$	(515,936)	$	(48,961)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

Senseonics Holdings, Inc.

Unaudited Condensed Consolidated Statements of Cash Flows

(in thousands)

Six Months Ended

June 30,


2019

2018

Cash flows from operating activities

Net loss

$
(60,439)

$
(54,769)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization expense

418

104

Non-cash interest expense (debt discount and deferred costs)

1,830

1,519

Change in fair value of derivative liability

(6,961)

15,012

Stock-based compensation expense

4,257

3,058

Provision for lower of cost or net realizable value

80

202

Provision for inventory obsolescence

2,256

—

Net realized gain on marketable securities

—

(69)

Changes in assets and liabilities:

Accounts receivable

1,295

394

Prepaid expenses and other current assets

(2,106)

(2,103)

Inventory

(8,892)

(5,611)

Deposits and other assets

—

(76)

Accounts payable

372

(2,540)

Accrued expenses and other current liabilities

2,626

4,118

Payments on right of use liability, building

(201)

—

Deferred revenue

(628)

—

Term Loans, accrued interest

238

390

    Deferred rent

—

4

Net cash used in operating activities

(65,855)

(40,367)

Cash flows from investing activities

Capital expenditures

(736)

(176)

Purchases of marketable securities

—

(7,935)

Sales and maturities of marketable securities

—

20,350

Net cash (used in) provided by investing activities

(736)

12,239

Cash flows from financing activities

Proceeds from issuance of common stock, net of issuance costs

—

149,379

Proceeds from exercise of stock options and stock warrants

94

813

Proceeds from 2023 Notes, net of costs

—

50,734

Principal payments on Term Loans

(5,000)

(5,000)

Principal payments under capital lease obligations

—

(20)

Net cash (used in) provided by financing activities

(4,906)

195,906

Net (decrease) increase in cash and cash equivalents

(71,497)

167,778

Cash and cash equivalents, at beginning of period

136,793

16,150

Cash and cash equivalents, at end of period

$
65,296

$
183,928

Supplemental disclosure of cash flow information

Cash paid during the period for interest

$
1,858

$
954

Supplemental disclosure of non-cash investing and financing activities

Common stock offering costs incurred

$
—

$
282

Convertible debt offering costs incurred

$
—

$
29

Property and equipment purchases included in accounts payable and accrued expenses

$
170

$
73


	Three Months Ended
	March 31,
	2020		2019
Cash flows used in operating activities
Net loss	$	(42,593)	$	(29,365)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense		288		200
Non-cash interest expense (debt discount and deferred costs)		2,191		909
Loss on extinguishment of debt		4,546		—
Change in fair value of derivative liabilities		(10,311)		(2,072)
Stock-based compensation expense		1,869		2,025
Provision for inventory obsolescence and net realizable value		12,551		56
Loss on disposal of assets		181		—
Changes in assets and liabilities:
Accounts receivable		9,384		4,730
Prepaid expenses and other current assets		(1,229)		(713)
Inventory		(617)		(4,195)
Deposits and other assets		(57)		3
Accounts payable		(1,795)		(1,133)
Accrued expenses and other liabilities		(2,305)		(97)
Deferred revenue		—		(628)
Accrued interest		(1,151)		128
Net cash used in operating activities		(29,048)		(30,152)
Cash flows used in investing activities
Capital expenditures		(100)		(392)
Payments on right of use liability, building		—		(98)
Net cash used in investing activities		(100)		(490)
Cash flows used in financing activities
Proceeds from issuance of common stock		117		—
Common stock issuance costs		(204)		—
Proceeds from exercise of stock options and stock warrants		498		23
Repayment of term loans		(48,396)		(2,499)
Net cash used in financing activities		(47,985)		(2,476)
Net decrease in cash, cash equivalents and restricted cash		(77,133)		(33,118)
Cash, cash equivalents and restricted cash, at beginning of period		95,938		136,793
Cash, cash equivalents and restricted cash, at ending of period	$	18,805	$	103,675

Supplemental disclosure of cash flow information
Cash paid during the period for interest	$	3,344	$	1,705
Supplemental disclosure of non-cash investing and financing activities
Property and equipment purchases included in accounts payable and accrued expenses	$	48	$	—

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

Senseonics Holdings, Inc.

Notes to Unaudited Condensed Consolidated Financial Statements

1.Organization and Nature of Operations

Senseonics Holdings, Inc., a Delaware corporation, is a medical technology company focused on the ~~design,~~ development and commercialization of long-term, implantable continuous glucose monitoring (“CGM”) systems to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy.

Senseonics, Incorporated is a ~~wholly-owned~~wholly owned subsidiary of Senseonics Holdings and was originally incorporated on October 30, 1996 and commenced operations on January 15, 1997. Senseonics Holdings and Senseonics, Incorporated are hereinafter collectively referred to as the “Company” unless otherwise indicated or the context otherwise requires.

~~2.Liquidity~~2.Going Concern and Liquidity Update

The Company’s operations are subject to certain risks and uncertainties including, among others, current and potential competitors with greater resources, lack of operating history and uncertainty of future profitability. Since inception, the Company has ~~incurred~~suffered substantial operating losses, principally from expenses associated with the Company’s research and development ~~programs.~~programs and commercial launch of Eversense® CGM System (for use up to 90 days) in the United States and the Eversense CGM and Eversense XL CGM Systems (for use up to 180 days) in Europe, the Middle East, and Africa. The Company has not generated significant ~~revenues~~revenue from the sale of products and its ability to generate revenue and achieve profitability largely depends on the Company’s ability ~~alone or with others,~~ to ~~complete~~successfully expand the commercialization of Eversense, continue the development of its products orand product ~~candidates,~~upgrades, and to obtain necessary regulatory approvals for the ~~manufacture, marketing and sales~~sale of those ~~products.~~products, including approval by the FDA for the extended Eversense XL CGM system in the United States. These activities will require significant uses of working capital through ~~the remainder of 2019~~2020 and beyond.

~~At June 30, 2019,~~The Company generated a net loss of $42.6 million for the three months ended March 31, 2020 and had an accumulated deficit of $515.9 million at March 31, 2020. Following the repayment in full of its term loan with Solar Capital Ltd. (“Solar”) in the amount of $48.5 million on March 22, 2020, the Company had ~~$65.3~~$18.8 million of cash, cash equivalents and restricted cash at March 31, 2020. As a result, and in ~~cash and cash equivalents. In July 2019,~~consideration of the evolving impact of the coronavirus (“COVID-19”) pandemic, the Company ~~completed financing~~made reductions in its cost structure to improve operating cash flow and ~~debt transactions totaling gross proceeds~~generate future capital expenditure savings to ensure the long-term success of ~~$106.2 million, after repayment~~Eversense. Specifically, the Company temporarily suspended commercial sales of the ~~Term Loans (as defined below)~~Eversense CGM system in the United States to new patients and streamlined its operational strategy to focus on the development and regulatory submission efforts for its Eversense XL CGM system, for use for up to 180 days, in the United States. In connection with these actions, on March 26, 2020, the Company reduced its workforce by approximately 60%, over half of which were sales personnel.

The Company is pursuing strategic alternatives and has been in discussions with new financing sources. Additional financing could include issuing additional equity (including through the Open Market Sales agreement with Jefferies) or either secured or unsecured indebtedness or a ~~portion~~combination of ~~the Company’s convertible senior subordinated notes due 2023 (the “2023 Notes”), as~~both.

Given its limited cash resources, and after inclusion of its subsequent financings described in Note 13 – Subsequent ~~Events. As a result of these transactions, management~~Events, and also considering the economic and market uncertainty resulting from COVID-19, the Company has ~~concluded that, based on the Company’s current operating plans,~~substantial doubt regarding its ~~existing cash and cash equivalents, will be sufficient~~ability to meet its obligations as they become due in the ordinary course of business for the next twelve months from the date of this Quarterly Report on Form 10-Q. The Company’s ~~anticipated operating needs through~~ability to generate enough cash to meet its streamlined working capital requirements is dependent on its ability to achieve additional capital sources and favorable outcomes from potential strategic alternatives currently being explored. New financings may not be available to the ~~end of 2020. Accordingly, management has concluded that~~Company on commercially acceptable terms, or at all, and may be impacted by the current debt covenants. The Company’s plans to alleviate its substantial doubt about ~~the Company’s~~its ability to continue as a going concern ~~over the next twelve months has been alleviated.~~assume that there will be no material adverse development in its business, liquidity, or capital requirements, or additional material adverse impacts from COVID-19.

~~Historically, the Company has financed its operating activities through the sale~~

Table of equity and equity linked securities and the issuance of debt. The Company plans to continue financing its operations with external capital for the foreseeable future. However, the Company may not be able to raise additional funds on acceptable terms, or at all. If the Company is unable to secure sufficient capital to fund its research and development and other operating activities, the Company may be required to delay or suspend operations, enter into collaboration agreements with partners that could require the Company to share commercial rights to its products to a greater extent or at earlier stages in the product development process than is currently intended, merge or consolidate with other entities, or liquidate.Contents

3.Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited ~~interim condensed~~ consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”)~~. In~~ for interim financial information and the ~~Company’s opinion,~~instructions to Form 10-Q and Article 10 of Regulation S-X. Although the ~~accompanying~~Company considers the disclosures in these unaudited ~~interim condensed~~ consolidated financial statements ~~include all adjustments, consisting of normal recurring adjustments, which are necessary~~ to present fairly its financial position, results of operations, and cash flows. The consolidated balance sheet at December 31, 2018, has been derived from audited financial statements as of that date. The interim condensed consolidated results of operations arebe adequate to make the information presented not ~~necessarily indicative of the results that may occur for the full fiscal year. Certain~~misleading, certain information ~~and~~or footnote ~~disclosure~~information normally included in consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted ~~pursuant to instructions,~~as permitted under the rules and regulations ~~prescribed by~~of the ~~U.S.~~United States Securities and Exchange Commission (“SEC”). In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair statement of financial position at March 31, 2020 and December 31, 2019 and results of operations for the three months ended March 31, 2020 and 2019, and cash flows for the three months ended March 31, 2020 and 2019 have been included. The ~~Company believes that the disclosures provided herein are adequate to make the information presented not misleading when these~~ unaudited

~~Table of Contents~~

~~interim~~ condensed consolidated financial statements ~~are~~should be read in conjunction with ~~the audited financial statements and notes previously included in~~ the Company’s Annual Report on Form 10-K for the year ended December 31, ~~2018.~~2019, as filed with the SEC on March 16, 2020, and amended on April 28, 2020. The interim results for March 31, 2020 are not necessarily indicative of the results to be expected for the year ending December 31, 2020 or for any future interim periods.

The consolidated financial statements reflect the accounts of Senseonics Holdings, Inc. and its wholly owned operating subsidiary Senseonics Incorporated.

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of ~~revenues~~revenue and expenses during the reporting period. In the accompanying unaudited consolidated financial statements, estimates are used for, but not limited to, stock-based compensation, recoverability of long-lived assets, deferred taxes and valuation allowances, derivative liabilities, obsolete inventory, warranty obligations, variable consideration related to revenue, depreciable lives of property and equipment, and ~~estimated~~ accruals for clinical study costs, which are accrued based on estimates of work performed under ~~contract~~.contract. The Company considered COVID-19 related impacts to its estimates, as appropriate, within its unaudited consolidated financial statements and there may be changes to those estimates in future periods due to the uncertainties surrounding the severity and duration of the COVID-19 pandemic. Actual results could differ from those estimates; however, management does not believe that such differences would be material.

Segment Information

Operating segments are defined as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one segment, glucose monitoring products.

Comprehensive Loss

Comprehensive loss comprises net loss and other changes in equity that are excluded from net loss. For the three ~~and six~~ months ended ~~June 30,~~March 31, 2020 and 2019, ~~and 2018,~~ the Company’s net loss equaled its comprehensive loss and, accordingly, no additional disclosure is presented.

Table of Contents

Cash and Cash Equivalents ~~and Concentration of Credit Risk~~

The Company considers highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents. These investments are carried at cost, which approximates fair value. Cash and cash equivalents consisted of the following as of the periods listed below (in thousands):


	March 31,		December 31,
	2020		2019
Cash ⁽¹⁾	$	12,308	$	38,043
Money market funds		1,500		37,769
Commercial paper		4,797		13,870
Corporate bonds		—		6,256
Cash and cash equivalents	$	18,605	$	95,938

⁽¹⁾ Includes overnight repurchase agreements

Restricted Cash

The Company’s restricted cash ~~and~~includes pledged cash ~~equivalents potentially subject the Company~~as collateral related to its credit ~~and liquidity risk. The Company maintains cash deposits at major financial institutions~~card program with high credit quality and, at times, the balances of those deposits may exceed the Federal Deposit Insurance Corporation limits of $250,000. The Company has not experienced and does not anticipate any losses on deposits with commercial banks and financial institutions that exceed the federally insured amounts.

~~Concentration of Revenues and Customers~~

At any given time, the Company’s trade receivables are concentrated among a small number of principal customers. If any of the Company’s customers fail to pay their obligations under the terms of these financial instruments, the Company’s maximum exposure to potential losses would be equal to amounts reported on its consolidated balance sheets.

During the three and six months ended June 30, 2019 and 2018, the Company derived a majority of its total net revenue from two customers. During the three months ended June 30, 2019 and 2018, the Company derived 68 percent and 85 percent of its total net revenue from one of those two customers, respectively. During the six months ended June 30, 2019 and 2018, the Company derived 66 percent and 86 percent of its total net revenue from one of those two customers, respectively.

~~Revenues by geographic region~~

Silicon Valley Bank. The following table ~~sets forth net revenues derived from~~provides a reconciliation of cash, cash equivalents and restricted cash reported within the ~~Company’s two primary geographical markets,~~consolidated balance sheets that sum to the ~~United States and outside~~total of the ~~United States, based on~~same such amounts shown in the ~~geographic location to which the Company delivers the~~

~~Table~~statement of ~~Contents~~

~~product, for the three and six months ended June 30, 2019. All of the Company’s net revenues were earned from sales outside of the United States for the three and six months ended June 30, 2018.~~cash flows (in thousands):

Three Months Ended

Six Months Ended

June 30, 2019

June 30, 2019

%

%

(Dollars in thousands)
Amount

of Total

Amount

of Total

Revenues, net:

Outside of the United States
$
3,509

76.2
%

$
6,117

76.2
%
United States

1,098

23.8

1,913

23.8

Total
$
4,607

100.0
%

$
8,030

100.0
%


	March 31,		December 31,
	2020		2019
Cash and cash equivalents	$	18,605	$	95,938
Restricted cash		200		—
Cash, cash equivalents and restricted cash	$	18,805	$	95,938

~~Inventory~~

Inventory is valued at the lower of cost or net realizable value. Cost is determined using the standard cost method that approximates first in, first out. The Company periodically reviews inventory to determine if a write-down is necessary for inventory that has become obsolete, inventory that has a cost basis less than net realizable value, and inventory in excess of future demand taking into consideration the product shelf life.

~~Accounts Receivable~~

The Company grants credit to various customers in the normal course of business. Accounts receivable consist of amounts due from distributors. The Company records an allowance for doubtful accounts at the time potential collection risk is identified. Uncollectible accounts are written off against the allowance after appropriate collection efforts have been exhausted and when it is deemed that a balance is uncollectible.

~~Property and Equipment~~

Property and equipment are stated at cost. Depreciation is computed by use of the straight-line method over the estimated useful lives of the assets, which is between three to five years for laboratory equipment, between five to seven years for office furniture and equipment, and the shorter of lease term or useful life for leasehold improvements. Upon disposition of the assets, the costs and related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations. Repairs and maintenance costs are included as expense in the accompanying statement of operations.Long-lived Assets

Management reviews long-lived assets, including property and equipment and right-of-use assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. ~~Recoverability~~As a result of COVID-19 and the ~~long-lived asset is measured by a comparison of~~events described above in Note 2, the ~~carrying amount of~~Company concluded the asset to future undiscounted net cash flows expected to be generated by the asset. If the undiscounted cash flows are less than the carrying amount, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the estimated fair value of ~~the assets. Management~~some of its property and equipment did not ~~identify any indicators~~exceed its carrying values. Accordingly, a loss on disposal of ~~impairment through June 30, 2019.~~

~~Derivative Financial Instruments~~

~~In connection with~~property and equipment in the ~~Company’s issuance~~amount of $0.2 million for the ~~2023 Notes in January 2018, the Company bifurcated the embedded conversion option, along with the interest make-whole provision and make-whole fundamental change provision, and~~three months ended March 31, 2020 was recorded ~~the embedded conversion option as a derivative liability~~ in the Company’s consolidated ~~balance sheets in accordance with Accounting Standards Codification (“ASC”) Topic 815,~~ ~~Derivatives and Hedging. The financial instrument is remeasured at the end of each reporting period with changes in fair value recorded in the consolidated statements~~statement of operations ~~in other income (expense) as change in fair value of 2023 derivative.~~

~~Table of Contents~~

~~In July 2019, the Company issued $82.0 million in aggregate principal amount of convertible senior subordinated notes due 2025 (the “2025 Notes”).~~ The Company used $37.9 million of the net proceeds from the issuance of the 2025 Notes to repurchase $37.0 million aggregate principal amount of the Company’s outstanding 2023 Notes, at a purchase price equal to the principal amount thereof, plus accrued and ~~unpaid interest thereon, as described in Note 13 – Subsequent Events.~~

~~Warranty Reserve~~

The Company may replace Eversense system components that do not function in accordance with the product specifications. Estimated replacement costs associated with a product are recorded at the time of shipment. The Company estimates future replacement costs by analyzing historical replacement experience for the timing and amount of returned product, and the Company evaluates the reserve quarterly and makes adjustments when appropriate.comprehensive loss.

Revenue ~~Recognition~~

The Company recognizes revenue ~~in accordance with ASC Topic 606,~~ ~~Revenue from Contracts with Customers~~. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under ASC Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition, ~~for arrangements that an entity determines are within the scope of ASC Topic 606,~~ the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, ~~once the contract is determined to be within the scope of ASC Topic 606,~~ the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

The Company generates ~~product~~ revenue from sales of the Eversense CGM system and related components ~~and supplies~~ at a fixed price to third-party distributors in the European Union and to a network of strategic fulfillment partners in the United States (collectively, “Customers”) who then resell the products to health care providers and patients. The Company is

Table of Contents

paid for its sales directly to the Customers, regardless of whether or not the Customers resell the products to health care providers and patients. Customer contracts do include the right to return.

~~Revenues from product sales are~~Revenue is recognized, at a point in time, when the Customers obtain control of the ~~Company’s~~ product ~~which occurs at a point in time,~~ based upon the delivery terms as defined in the ~~distributor agreement.~~contract at an amount that reflects the consideration which is expected to be received in exchange for the product. Contracts with the Customers include performance obligations for supply of goods and the performance obligation is typically satisfied upon transfer of control of the product. Distribution contracts may also contain requirements for training and customer service support, however these are not assessed as performance obligations given the activities are considered immaterial in the context of the contract. The payment terms and conditions of the Customers vary, but the Company is typically paid within 60 days of invoicing subsequent to the Customers obtaining control of the Company’s product.

~~In March 2019,~~Revenue is recognized only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur in a future period. The Company’s contracts may contain variable consideration such as prompt-pay discounts or tier-volume price discounts. Variable consideration, including the reimbursements paid by the Company ~~introduced~~to its Customers in accordance with the Eversense Bridge Program ~~(the “program”)~~initiated in ~~the United States. Under the program, the Company provides financial assistance, in the form of reimbursement,~~March 2019 and to ~~eligible patients based on their insurance coverage. Reimbursement payments to the patient under the program are~~a lesser extent, other discounts and prompt-pay incentives, is treated as a reduction in revenue when the product sale is recognized. Depending on the variable consideration, the Company estimates the expected value based on the terms of ~~revenue~~the agreements, historical data, insurance payor mix, reimbursement rates, and market conditions. In connection with the Eversense Bridge Program, the Company reimburses participating Customers an amount up to a fixed maximum for the difference in the ~~period in~~cost of the Eversense System and what they collect from insurance payors and the patient’s fee of $99. The Customers are responsible for confirming patient insurance coverage, obtaining pre-authorizations, determining eligibility, and continuously provide the Company with data regarding which patient orders are under the ~~corresponding gross revenue is recognized.~~program and which are not. Customer supplied data, along with actual reimbursements that have been validated to patient claims, are used to support expected reimbursement estimates. Estimated reimbursement payments for product shipped to ~~the Company’s customers~~Customers but not ~~sold~~provided to a patient within the same reporting period ~~is based on historical experience and~~are recorded within accrued expenses and other current liabilities in the accompanying consolidated balance sheets. Because of the limited experience with the ~~program as of June 30, 2019,~~Eversense Bridge Program, the ~~Company’s estimated reimbursement rates with respect to such shipped, but unsold, products~~estimates used in determining the variable consideration on a sale transaction could change in future periods, and such changes could be material. ~~The Company also, at its discretion, offers discounts~~

Contract assets consist of trade receivables from Customers and ~~other allowances under defined promotional~~contract liabilities consist of amounts due to Customers in connection with the Eversense Bridge Program, classified as patient access and incentive programs towithin accrued liabilities on the ~~Customers which result~~accompanying unaudited consolidated balance sheets. Trade receivables for customers in the ~~establishment~~United States are recorded at net realizable value, which is generally the contractual price but may be net of ~~reserves against product revenue.~~anticipated prompt-pay or promotional discounts.

~~Table~~Concentration of ~~Contents~~

Revenue and Customers

~~Cost of Sales~~

For the three months ended March 31, 2020 and 2019, the Company derived 0% and 59%, respectively, from one customer, Roche Diabetes Care GmbH.

Revenue by Geographic Region

The Company uses third-party contract manufacturers to manufacture Eversense and related components and supplies. Cost of sales includes raw materials, contract manufacturing service fees, reserves for expected warranty costs, reserves for inventory valuation and obsolescence, scrap, and shipping and handling expenses associated with product delivery.

~~Research and Development Costs~~

Research and development costs are expensed as incurred. Research and development expenses include costs related to employee compensation, consultants, contracted services, supplies, outsourced testing, depreciation and other expenses associated withfollowing table sets forth net revenue derived from the Company’s ~~process development, clinical, regulatory,~~two primary geographical markets, the United States and ~~quality assurance activities.~~

~~Stock‑Based Compensation~~

~~The Company recognizes~~outside of the ~~cost of employee services received in exchange for awards of equity instruments, such as stock options,~~United States, based on the ~~fair value of those awards at~~geographic location to which the ~~date of grant. The estimated fair value of stock options on~~Company delivers the ~~date of grant is amortized on a straight‑line basis over~~product, for the requisite service period for each separately vesting portion of the award for those awards with service conditions only. For awards that also contain performance conditions, expense is recognized beginning at the time the performance condition is considered probable of being met over the remaining vesting period. The Company accounts for forfeitures in the period in which they occur.three months ended March 31, 2020 and 2019.

The Company uses the Black‑Scholes option pricing model to determine the fair value of stock‑option awards. Valuation of stock awards requires management to make assumptions and to apply judgment to determine the fair value of the awards. These assumptions and judgments include estimating the fair value of the Company’s common stock, future volatility of the Company’s stock price, dividend yields, future employee turnover rates, and future employee stock option exercise behaviors. Changes in these assumptions can affect the fair value estimate.


	March 31, 2020				March 31, 2019
			%				%
(Dollars in thousands)	Amount		of Total		Amount		of Total
Revenue, net:
Outside of the United States	$	12	33.3	%	$	2,607	76.2	%
United States		24	66.7			816	23.8
Total	$	36	100.0	%	$	3,423	100.0	%

Under ASC Topic 718, the cumulative amount of compensation cost recognized for instruments classified as equity that ordinarily would result in a future tax deduction under existing tax law shall be considered to be a deductible difference in applying ASC Topic 740, ~~Income Taxes~~. The deductible temporary difference is based on the compensation cost recognized for financial reporting purposes; however, these provisions currently do not impact the Company, as all the deferred tax assets have a full valuation allowance.

Since the Company had net operating loss (“NOL”) carryforwards as of June 30, 2019, no excess tax benefits for the tax deductions related to stock-based awards were recognized in the statements of operations and comprehensive loss.

~~Income Taxes~~

The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that are in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that such tax rate changes are enacted. The measurement of a deferred tax asset is reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized.

Management uses a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return, as well as guidance on derecognition, classification, interest and penalties and financial statement reporting disclosures. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. In the ordinary course of business, transactions occur for which the ultimate outcome may be uncertain. Management does not expect the outcome related to accrued uncertain tax provisions to have a material adverse effect on the Company’s financial position, results of operations or cash flows. The Company recognizes interest and penalties accrued on any

Table of Contents

~~unrecognized tax exposures as a component~~

Accounts Receivable

Accounts receivable consist of ~~income tax expense.~~amounts due from the Company’s Customers and are recorded at net realizable value, which may include reductions for allowances for doubtful accounts at the time potential collection risk is identified or for promotional or prompt-pay discounts offered. The Company ~~did not have any amounts accrued relating~~provided one-time COVID-19 pandemic relief concessions to ~~interest and penalties as~~some of ~~June 30, 2019 and December 31, 2018.~~

~~The Company is subject to taxation in various jurisdictions~~its customers in the United States for allowances up to a specified amount if they are unable to sell through Eversense and ~~remains subject~~related components on hand prior to ~~examination~~expiry, which the Company expects to occur in the third and fourth quarters of 2020. The Company’s net revenues and corresponding accounts receivables were reduced by ~~taxing jurisdictions~~$1.2 million for ~~the year 1998~~these allowances at March 31, 2020. The Company does not have a history of collectability concerns and all subsequent periods due to the availability of NOL carryforwards. In addition, all of the NOLs and research and development credit carryforwards that may be used in future years are still subject to adjustment.

~~Fair Value of Financial Instruments~~

~~The carrying amounts of cash and cash equivalents,~~there have been no provisions for uncollectible accounts recorded against accounts receivable ~~accounts payable, and accrued expenses approximate fair value because of their short maturities. The Company’s Notes and 2023 Notes are recorded~~ at ~~historical cost, net of discounts, and are not remeasured at fair value.~~March 31, 2020 or December 31, 2019.

Net Loss per Share

Basic net loss per share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period.

For periods of net loss, diluted net loss per share is calculated similarly to basic loss per share because the impact of all potential common shares is anti-dilutive. ~~At June 30, 2019 and 2018, the~~The total number of anti-dilutive shares at March 31, 2020 and 2019, consisting of common stock options and stock purchase warrants, ~~and the 2023 Notes using the if-converted method,~~ which have been excluded from the computation of diluted net loss per share, ~~were~~was as follows:


	June 30,		March 31,
	2019	2018	2020	2019
Stock-based awards	27,618,668	21,305,247	18,918,008	27,518,174
2023 Notes	21,321,038	15,499,998	6,672,500	20,017,048
2025 Notes			63,018,091	—
Warrants	4,071,581	4,082,544	5,196,581	4,071,581
Total anti-dilutive shares outstanding	53,011,287	40,887,789	93,805,180	51,606,803

For periods of net income, and when the effects are not anti-dilutive, diluted earnings per share is computed by dividing net income available to common stockholders by the weighted-average number of shares outstanding plus the impact of all potential dilutive common shares, consisting primarily of common stock options ~~and~~ stock purchase warrants and employee stock purchases using the treasury stock ~~method, and the 2023 Notes using the if-converted~~ method.

~~Recent Accounting Pronouncements~~Exit or Disposal Costs

~~Recently Adopted~~

~~In February 2016,~~Costs associated with exit or disposal activities, such as restructuring, sale or termination of a line of business, the ~~Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842) (“ASC 842”). The guidance requires lessees to recognize assets~~closure of business activities in a particular location, the relocation of business activities, changes in management structure and ~~liabilities related to long-term leases on~~a fundamental reorganization that affects the ~~balance sheet~~nature and expands disclosure requirements regarding leasing arrangements. In July 2018, the FASB issued ASU 2018-11 to provide another transition method, allowing a cumulative effect adjustment to the opening balancefocus of ~~retained earnings~~operations, are recognized and measured initially at their fair values during the period in which an obligation meets the definition of ~~adoption. The guidance is effective for annual reporting periods beginning after December 15, 2018, subject~~a liability. As a result of the Company’s financial condition following the repayment in full of its term loan with Solar on March 22, 2020, further described above in Note 2 – Going Concern and Liquidity Update, and in consideration of the economic uncertainty due to ~~early adoption. The~~the COVID-19 pandemic, the Company ~~adopted~~made reductions in its cost structure and operational focus to improve operating cash flow and generate future capital expenditure savings to ensure the ~~new standard effective January 1, 2019 using the modified retrospective approach. The Company~~long-term success of Eversense. These cost reductions included a reduction in force by approximately 60%, which was communicated to employees on March 26, 2020 and did not ~~elect~~permit continuation of service past March 31, 2020. Associated one-time employee termination benefit costs in the ~~transition option, but elected certain practical expedients, including not separating lease components from nonlease components for all classes~~amount of ~~underlying assets. Additionally, all leases with a term at commencement of 12 months or less will be excluded from analysis under ASC 842. The standard did not materially affect~~$1.6 million were accrued and recorded in the Company’s accompanying unaudited consolidated ~~net loss or cash flows.~~

financial statements as of March 31, 2020.

Table of Contents

~~Impact of Adopting ASC 842 on~~Recent Accounting Pronouncements

Recently Adopted

In August 2018, the Financial ~~Statements~~

January 1, 2019

January 1, 2019


Prior to ASC




��

842 Adoption

ASC 842 Adoption

As Adjusted
Consolidated Balance Sheet Data (in thousands)

Operating lease assets (1)

$
—

$
2,235

$
2,235
Deferred rent non-current (2)

$
84

$
(84)

$
—
Operating lease liabilities (3)

$
—

$
417

$
417
Non-current operating lease liabilities (3)

$
—

$
1,902

$
1,902

~~(1) Represents capitalization of operating lease assets, including reclassification of deferred rent~~Accounting Standards Board (“FASB “) issued Accounting Standards Update (“ASU”) 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework – Changes to ~~operating lease assets.~~

~~(2) As of December 31, 2018,~~ the ~~deferred rent balance was $84.~~

~~(3) Represents recognition of operating lease liabilities.~~

Disclosure Requirements for Fair Value Measurement, which eliminates, adds and modifies certain disclosure requirements on fair value measurements. The new standard includes additional disclosure requirements regarding the range and weighted average to develop significant unobservable inputs within Level 3 fair value measurements. The Company ~~has evaluated all other issued unadopted ASUs~~adopted this on its effective date, January 1, 2020 and ~~believes the adoption of these standards will~~did not have a material impact on ~~its~~the consolidated financial statements ~~of earnings, balance sheets, or cash flows.~~and related disclosures.

Not Yet Adopted

In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses: Measurement of Credit Losses on Financial Instruments, which requires entities to record expected credit losses for certain financial instruments, including trade receivables, as an allowance that reflects the entity's current estimate of credit losses expected to be incurred. For available-for-sale debt securities in unrealized loss positions, the new standard requires allowances to be recorded instead of reducing the amortized cost of the investment. The Company does not currently hold or plan to invest in available-for-sale securities and has not historically experienced collection issues or bad debts with trade receivables. Accordingly, the Company does not expect this to have a significant impact on its consolidated financial statements and related disclosures at this time. The Company will adopt this guidance on its effective date for smaller reporting companies, January 1, 2023.

In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes, which is intended to simplify various aspects of the income tax accounting guidance, including requirements such as tax basis step-up in goodwill obtained in a transaction that is not a business combination, ownership changes in investments, and interim-period accounting for enacted changes in tax law. ASU 2019-12 is effective for public business entities for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years, and early adoption is permitted. The Company is currently evaluating the impact that this guidance will have on its consolidated financial statements.

4. Inventory, net

Inventory, net of reserves, consisted of the following (in thousands):


	June 30,		December 31,		March 31,		December 31,
	2019		2018		2020		2019
Finished goods	$	1,707	$	1,457	$	1,043	$	3,944
Work-in-process		13,518		7,211		1,282		10,938
Raw materials		1,562		1,563		2,670		2,047
Total	$	16,787	$	10,231	$	4,995	$	16,929

The Company charged $15.0 million and $0.1 million to cost of sales for the three months ended March 31, 2020 and 2019, respectively, to reduce the value of inventory for items that are potentially obsolete, in excess of product demand, or to adjust costs to their net realizable value.

5. Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following (in thousands):

June 30,

December 31,

2019

2018
Contract manufacturing

$
3,614

$
2,962
Financing services

712

—
Marketing and sales

598

287
Insurance

442

—
Clinical and preclinical

257

111
IT and software

199

244
Interest receivable

100

239
Other

169

142
Total prepaid expenses and other current assets

$
6,091

$
3,985


	March 31,		December 31,
	2020		2019
Contract manufacturing	$	3,723	$	3,043

Table of Contents

Insurance		1,040		44
Marketing and sales		534		605
Clinical and preclinical		216		240
IT and software		202		294
Interest receivable		18		107
Other		7		179
Total prepaid expenses and other current assets	$	5,740	$	4,512

6.Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):

June 30,

December 31,

2019

2018
Contract manufacturing

$
4,299

$
6,068
Compensation and benefits

3,457

3,685
Sales and marketing services

1,942

738
Professional services

1,586

727
Clinical and preclinical

1,472

147
Product warranty

1,386

816
Interest on notes payable and 2023 Notes


1,226


1,268
Patient access program

831

—
Right of use liability - building

445

—
Other

278

402
Total accrued expenses and other current liabilities

$
16,922

$
13,851


	March 31,		December 31,
	2020		2019
Compensation and benefits⁽¹⁾	$	3,496	$	5,630
Contract manufacturing		3,274		2,452
Product warranty and replacement obligations		2,157		2,197
Professional & administration services		1,856		1,384
Research and development		1,140		1,956
Patient access programs		1,053		1,578
Interest on notes payable		1,001		2,153
Operating lease		719		696
Sales and marketing services		625		553
Other		50		37
Total accrued expenses and other current liabilities	$	15,371	$	18,636

⁽¹⁾Includes $1.6 million for one-time employee termination benefits associated with the Company’s reduction in force on March 26, 2020

~~7.Leases~~7.Notes Payable and Stock Purchase Warrants

~~The Company leases approximately 33,000 square feet~~Repayment of ~~research and office space under a non‑cancelable operating lease expiring in 2023. The Company has an option to renew the lease for one additional five‑year term.~~ ~~With the adoption of ASC 842,~~Solar Term Loan

On March 22, 2020, the Company ~~has recorded a right-of-use asset~~ and ~~corresponding lease liability,~~Solar terminated its Loan and ~~does not include~~Security Agreement, dated as of July 16, 2019 (the “Solar Loan Agreement”). As previously disclosed in the ~~additional five year term~~Company’s Annual Report on Form 10-K, the Company expected to default on its obligations under the ~~option.~~

~~The Company leases approximately 12,000 square feet~~Solar Loan Agreement and was seeking a waiver from Solar of ~~office space~~any default under the Solar Loan Agreement. Following discussions with Solar, the parties were unable to negotiate such a ~~cancelable operating lease that expired on June 30, 2019~~waiver and, ~~is now~~as a ~~cancellable month-to-month operating lease. The Company can terminate~~result, the ~~lease agreement upon 60 days’ prior written notice.~~

Operating lease expense for the three and six months ended June 30, 2019 was $0.2 million and $0.3 million, respectively. Short-term lease expense is included in total lease expense but was not significant for the three and six months ended June 30, 2019.

~~Lease expense was $0.1 million and $0.3 million for the three and six months ended June 30, 2018, respectively.~~

~~The Company identified and assessed the following estimates in recognizing the right-of-use asset and corresponding liability:~~

~~Expected lease term~~: The expected lease term for those leases commencing prior to January 1, 2019 did not change with the adoption of ASC 842. The expected lease term for leases commencing after the adoption of ASC 842 includes noncancelable lease periods and, when applicable, periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option, as well as periods covered by an optionparties determined to terminate the ~~lease if~~Solar Loan Agreement.

In connection with the termination, the Company ~~is reasonably certain not~~paid $48.5 million representing all amounts outstanding under the Solar Loan Agreement, including the principal amount and interest of the loans, a payoff fee of 6.45% of the loans outstanding, a prepayment premium of 3.0% of the loans outstanding and other obligations owed to Solar thereunder. The Company issued warrants in connection to the Solar Loan Agreement to purchase an aggregate of 1,125,000 shares of the Company’s common stock with an exercise ~~that option.~~price of $1.20 per share, which are exercisable until July 25, 2029.

~~Incremental borrowing rate: As~~A loss on the ~~discount rates~~extinguishment of debt in the amount of $4.5 million reflecting the difference between the repayment amount and the carrying value of the principal balance, accrued interest, unamortized debt issuance costs and unaccreted prepayment fee at March 22, 2020 was recorded to other income (expense) in the Company’s ~~lease are not implicit,~~unaudited consolidated statement of operations and comprehensive loss during the ~~Company estimated the incremental borrowing rate based on the rate of interest the Company would have to pay to borrow a similar amount on a collateralized basis over a similar term.~~three months ended March 31, 2020.

Convertible Notes

2025 Notes

Table of Contents

~~The following table summarizes the lease assets and liabilities as of June 30,~~In July 2019, ~~(in thousands):~~

Operating Lease Assets and Liabilities

Balance Sheet Classification

Amount
Assets

Operating lease ROU assets

Deposits and other assets

$
2,025
Liabilities

Current operating lease liabilities

Accrued expenses and other current liabilities

$
445
Non-current operating lease liabilities

Other non-current liabilities

1,674
Total operating lease liabilities

$
2,119

~~The following table summarizes the maturity of undiscounted payments due under lease liabilities and the present value of those liabilities as of June 30, 2019 (in thousands):~~

2019 (remaining six months)

$
309
2020

629
2021

648
2022

668
2023

282
Total

2,536
Present value adjustment

(417)
Present value of lease liabilities

$
2,119

~~The following table summarizes the weighted-average lease term and weighted-average discount rate as of June 30, 2019:~~


~~Remaining lease term (years)~~
~~Operating leases~~	~~3.9~~
~~Discount rate~~
~~Operating leases~~	~~9.1~~	%

~~8.Notes Payable~~

~~Term Loans~~

~~On June 30, 2016,~~ the Company entered into an Amended and Restated Loan and Security Agreement with Oxford Finance LLC (“Oxford”) and Silicon Valley Bank (“SVB” and together with Oxford, the “Lenders”). Pursuant to the Amended and Restated Loan and Security Agreement, the Company borrowed anissued $82.0 million in aggregate principal amount of $25.0 million in the following three tranches: $15.0 million (“Tranche 1 Term Loan”); $5.0 million (“Tranche 2 Term Loan”); and $5.0 million (“Tranche 3 Term Loan”) (each, a “Term Loan,” and collectively, the “Term Loans”senior convertible notes that will mature on January 15, 2025, unless earlier repurchased or converted (the “2025 Notes”). The ~~funding conditions for~~2025 Notes are convertible, at the ~~Tranche 1 Term Loan were satisfied as~~option of ~~June 30, 2016. Therefore,~~ the ~~Company issued secured notes to the Lenders for aggregate gross proceeds~~holders, into shares of ~~$15.0 million (the “Notes”) on June 30, 2016. The Company used approximately $11.0 million from the proceeds from the Notes to repay the outstanding balance under~~ the Company’s previously existing Loan and Security Agreement with Oxford. The Company borrowed the Tranche 2 Term Loan and Tranche 3 Term Loan in November 2016 and March 2017, respectively. The maturity date for all Term Loans was June 1, 2020 (the “Maturity Date”).

On July 16, 2019, the Company entered into a Loan and Security Agreement (the “Solar Loan Agreement”) with Solar Capital, Ltd. a Maryland corporation (“Solar”), as described in Note 13 – Subsequent Events. Pursuant to the Solar Loan Agreement, on July 25, 2019, the Company borrowed term loans incommon stock, at an ~~aggregate~~initial conversion rate of 757.5758 shares per $1,000 principal amount of ~~$45.0~~

~~Table~~the 2025 Notes (equivalent to an initial conversion price of ~~Contents~~

~~million, of which the~~ ~~Company used $11.6 million~~ ~~to repay in full the Term Loans and terminate the~~ ~~Amended and Restated Loan and Security Agreement~~ ~~with Oxford and SVB.~~

The Term Loans bore interest at a floating annual rate of 6.31% plus the greater of (i) 90-day U.S. Dollar LIBOR reported in the Wall Street Journal or (ii) 0.64%, provided that the minimum floor interest rate is 6.95%, and require monthly payments. The monthly payments initially consisted of interest-only through December 31, 2017. In January 2018, the Company began to make monthly principal payments.

~~The Company elected to prepay all Term Loans prior to the Maturity Date subject to a prepayment fee equal to 1.00%.~~

The Amended and Restated Loan and Security Agreement contained customary events of default, including bankruptcy, the failure to make payments when due, the occurrence of a material impairment on the Lenders’ security interest over the collateral, a material adverse change, the occurrence of a default under certain other agreements entered into by the Company, the rendering of certain types of judgments against the Company, the revocation of certain government approvals of the Company, violation of covenants, and incorrectness of representations and warranties in any material respect.

Pursuant to the Amended and Restated Loan and Security Agreement, the Company also issued 10-year stock purchase warrants to purchase an aggregate of 260,251 shares of common stock with an exercise price ranging from $1.86 to $3.86approximately $1.32 per ~~share (see Note 9, “Stockholders’ Equity”)~~share).

The 2025 Notes ~~were collateralized by all of~~also contained an embedded conversion option requiring bifurcation as a separate derivative liability, along with the fundamental change make-whole provision and the cash settled fundamental make-whole shares provision. The derivative is adjusted to fair value at each reporting period, with the change in the fair value recorded to other income (expense) in the Company’s consolidated ~~assets. The Notes also contained certain restrictive covenants that limited the Company’s ability to incur additional indebtedness~~statement of operations and liens, merge with other companies or consummate certain changes of control, acquire other companies, engage in new lines of business, make certain investments, pay dividends, transfer or dispose of assets, amend certain material agreements or enter into various specified transactions, as well as financial reporting requirements. The Company incurred issuance costs related to the Notes of approximately $0.6 million that are being amortized as additional interest expense over the term of the Notes using the effective interest method. The fair value of the stock purchase warrants, which was estimated to be $0.5 million, was recorded as a discount to the Notes, which is also being amortized as additional interest expense over the term of the Notes using the effective interest method.

The Company was also required to make a final payment equal to 9.00% of the aggregate principal balances of the funded Term Loans. This fee is being accrued as additional interest expense over the term of the Notes using the effective interest method. At June 30, 2019 and December 31, 2018, the final payment fee accrual was $2.0 million and $1.8 million, respectively.

The Company estimates the fair value of the Notes based on borrowing rates currently available for loans with similar terms (Level 2). At June 30, 2019, the fair value of the Notes was $11.3 million based on prevailing market rates for secured debt.comprehensive loss.

2023 Notes

In ~~January~~the first quarter of 2018, the Company issued ~~$50.0~~$53.0 million in aggregate principal amount of ~~the~~senior convertible notes due February 1, 2023 ~~Notes.~~(the “2023 Notes”). In ~~February 2018,~~July 2019, the Company ~~issued an additional $3.0 million in aggregate principal amount of~~used the ~~2023 Notes, pursuant to the partial exercise of the overallotment option by the underwriter. The~~ net proceeds from the issuance of the ~~2023~~2025 Notes ~~after deducting transaction costs, were $50.7 million. The 2023 Notes are general, unsecured, senior subordinated obligations~~to repurchase $37.0 million aggregate principal amount of the ~~Company. The Company pays interest semiannually in arrears on February 1 and August 1 of each year, beginning on August 1, 2018. As the~~outstanding 2023 ~~Notes have a maturity date of February 1, 2023, they are classified as a long-term liability on the Company’s consolidated balance sheet at June 30, 2019.~~

Notes. Each $1,000 of principal of the 2023 Notes is initially convertible into 294.1176 shares of the Company’s common stock, which is equivalent to an initial conversion price of approximately $3.40 per share, subject to adjustment upon the occurrence of specified events. ~~Holders may convert at any time prior to February 1, 2023. Holders who~~

~~Table of Contents~~

convert on or after the date that is six months after the last date of original issuance of the 2023 Notes but prior to February 1, 2021, may also be entitled to receive, under certain circumstances, an interest make-whole payment payable in shares of common stock. If specific corporate events occur prior to the maturity date, the Company would increase the conversion rate pursuant to the make-whole fundamental change provision for a holder who elects to convert their 2023 Notes in connection with such an event in certain circumstances. Additionally, if a fundamental change occurs prior to the maturity date, holders of the 2023 Notes may require the Company to repurchase all or a portion of their 2023 Notes for cash at a repurchase price equal to 100% of the principal amount plus any accrued and unpaid interest.

~~In accordance with U.S. GAAP relating to embedded conversion features, the~~The Company bifurcated the embedded conversion option, along with the interest make-whole provision and make-whole fundamental change provision ~~and in January 2018 recorded the embedded conversion option~~ as a ~~debt discount and~~ derivative ~~liability in the Company’s consolidated balance sheets at its initial~~liability. The derivative is adjusted to fair value of $17.3 million. Additionally, the Company incurred transaction costs of $2.2 million. The debt discount, embedded conversion option and transaction costs, are being amortized to interest expense over the term of the 2023 Notes at an effective interest rate of 9.30%.

~~The derivative liability will be remeasured~~ at each reporting period, with ~~changes~~the change in the fair value recorded ~~in the consolidated statements of operations in~~to other income (expense).

~~In the second quarter of 2018, the Company issued 73,529 shares of common stock upon the conversion of $250,000 in aggregate principal amount of the 2023 Notes. There was no conversion of 2023 Notes~~ in the ~~second quarter~~Company’s consolidated statement of ~~2019.~~operations and comprehensive loss.

The following ~~are~~carrying amounts were outstanding under the ~~scheduled maturities of the 2023 Notes and Term Loans~~Company’s notes payable as of ~~June 30,~~March 31, 2020 and December 31, 2019 (in thousands):

2019 (remaining six months)

$
5,000

2020

5,000

2021

—

2022

—

2023

52,700

Total

$
62,700


	March 31, 2020
	Principal ($)	Debt Discount ($)	Issuance Costs ($)	Carrying Amount ($)
2023 Notes	15,700	(3,624)	-	12,076
2025 Notes	82,000	(45,006)	(686)	36,308

	December 31, 2019
	Principal ($)	Debt Discount ($)	Issuance Costs ($)	Carrying Amount ($)
Solar Term Loan	45,000	(1,466)	(100)	43,434
2023 Notes	15,700	(3,900)	-	11,800
2025 Notes	82,000	(46,482)	(708)	34,810

~~The Company estimates~~Interest expense related to the ~~fair value of~~notes payable for the ~~2023 Notes using commonly accepted valuation methodologies and market-risk measurements that are indirectly observable, such~~three months ended March 31, 2020 was as ~~credit risk (Level 2). At June 30, 2019, the fair value of the 2023 Notes, excluding the derivative liability, was $43.1 million.~~follows (in thousands):

~~In July 2019, the Company issued $82.0 million in aggregate principal amount of 2025 Notes.~~ The Company used $37.9 million of the net proceeds from the issuance of the 2025 Notes to repurchase $37.0 million aggregate principal amount of the Company’s outstanding 2023 Notes, at a purchase price equal to the principal amount thereof, plus accrued and unpaid interest thereon, as described in Note 13 – Subsequent Events.


	Three months ended March 31, 2020
	Effective Interest Rate	Interest ($)	Debt Discount & Fees ($)	Issuance Costs ($)	Final Payment Fee ($)	Total Interest Expense ($)
Solar Term Loan	8.98%	887	139	36	240	1,302
2023 Notes	5.25%	1,087	1,476	22	-	2,585
2025 Notes	5.25%	206	276	-	-	482
Total		2,180	1,891	58	240	4,369

~~9.Stockholders’ Equity~~

~~Preferred Stock~~

As of June 30, 2019 and December 31, 2018, the Company’s authorized capital stock included 5,000,000 shares of undesignated preferred stock, par value $0.001 per share. No shares of preferred stock were outstanding as of June 30, 2019 or December 31, 2018.

~~Common Stock~~

As of June 30, 2019 and December 31, 2018, the Company’s authorized capital stock included 450,000,000 shares of common stock, par value $0.001 per share. The Company had 177,031,842 and 176,918,381 shares of common stock issued and outstanding at June 30, 2019 and December 31, 2018, respectively.

1614

Table of Contents

~~Stock Purchase Warrants~~The following are the scheduled maturities of the 2025 Notes and 2023 Notes as of March 31, 2020 (in thousands):


2020 (remaining nine months)	$	—
2021		—
2022		—
2023		15,700
2024		—
Thereafter		82,000	⁽¹⁾
Total	$	97,700

~~In connection~~⁽¹⁾ On April 21, 2020 the Company entered into a Note Purchase and Exchange Agreement with certain funds managed by Highbridge Capital Management, LLC providing for the ~~issuance~~exchange of $24.0 million aggregate principal amount of the Company’s outstanding 2025 Notes ~~the Company also~~for (i) $15.7 million aggregate principal amount of newly issued ~~to the Lenders 10-year stock purchase~~Second Lien Secured Notes due January 2022, (ii) 11,026,086 shares of Common Stock, (iii) warrants to purchase ~~an aggregate of 116,581, 63,025 and 80,645~~up to 4,500,000 shares of ~~common stock~~Common Stock at an exercise price of ~~$3.86, $2.38 and $1.86~~$0.66 per share, ~~respectively. The cumulative fair value of~~and (iv) $0.3 million in accrued and unpaid interest on the ~~warrants, which~~2025 Notes being exchanged. See Note 13 below for more details.

8.Stockholders’ Deficit

In November 2019, the Company estimated to be $0.5 million, was recorded as a discount to the Notes. These warrants expire on June 30, 2026, November 22, 2026, and March 29, 2027, respectively, and are classified in equity. In connection with the Company’s original Loan and Securityentered into an Open Market Sale Agreement with ~~Oxford in 2014,~~Jefferies LLC which allows the Company ~~issued~~ to ~~Oxford 10-year stock purchase warrants~~issue and sell up to ~~purchase an aggregate~~$50 million in gross proceeds of ~~167,570~~its common stock. During the three months ended March 31, 2020 the Company sold 175,089 shares of common stock ~~at an exercise price of $1.79 per share. The fair value of the warrants, which the Company estimated to be $0.2 million, was recorded as a discount to the promissory notes issued to Oxford~~resulting in connection with the original Loan and Security Agreement. These warrants expire on November 2, 2020, July 14, 2021 and August 19, 2021, and are classified in equity. The unamortized deferred financing fees and debt discount related to the notes rollover amount is being amortized along with the deferred financing costs and the discount created by the new issuance of the warrants over the term of the loan using the effective interest method. For each of the six months ended June 30, 2019 and 2018, the Company recorded amortization of discount of debtgross proceeds of $0.1 ~~million within interest expense in the accompanying statements of operations and comprehensive loss.~~million.

9. Stock‑Based Compensation

2015 Plan

In December 2015, the Company adopted the 2015 Equity Incentive Plan (the “2015 Plan”), under which incentive stock options, non-qualified stock options and restricted stock ~~awards~~units may be granted to the Company’s employees and certain other persons in accordance with the 2015 Plan ~~provisions.~~provisions, such as officers and directors. In ~~connection with the March~~February 2016, ~~Offering,~~ the Company’s ~~board~~Board of ~~directors~~Directors adopted and the Company’s stockholders approved an Amended and Restated 2015 Equity Incentive Plan (the “amended and restated 2015 Plan”)~~. The amended and restated 2015 Plan~~, which became effective ~~as of the date of the pricing of the~~on March ~~2016 Offering.~~17, 2016. The Company’s board of directors may terminate the amended and restated 2015 Plan at any time. Options granted under the amended and restated 2015 Plan expire ten years after the date of grant.

Pursuant to the amended and restated 2015 Plan, the number of shares initially reserved for issuance pursuant to equity awards was 17,251,115 shares, representing 8,000,000 shares plus up to an additional 9,251,115 shares in the event that options that were outstanding under the Company’s equity incentive plans as of February 16, 2016 expire or otherwise terminate without having been exercised (in such case, the shares not acquired will revert to and become available for issuance under the amended and restated 2015 Plan). The number of shares of the Company’s common stock reserved for issuance ~~under the amended and restated 2015 Plan will~~ automatically ~~increase~~increases on January 1 of each year, ~~beginning on January 1, 2017 and~~ ending on January 1, 2026, by 3.5% of the total number of shares of ~~the Company’s~~its common stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares as may be determined by ~~the Company’s~~its board of directors. As of ~~June 30, 2019, 670,452~~March 31, 2020, 17,261,319 shares remained available for grant under the amended and restated 2015 Plan.

Inducement Plan

On May 30, 2019, the Company adopted the Senseonics Holdings, Inc. Inducement Plan (the “Inducement Plan”), pursuant to which the Company reserved 1,800,000 shares of the Company’s common stock for issuance. The only persons eligible to receive grants of ~~Awards (as defined below)~~awards under the Inducement Plan are individuals who satisfy the standards for inducement grants in accordance with NYSE American Company Guide Section 711(a), including individuals who were not previously an employee or director of the Company, or following a bona fide period of non-employment, as an inducement material to such persons entering into employment with the Company. An “Award” is any right to receive the Company’s common stock pursuant to the Inducement Plan, consisting of ~~nonstatutory~~non-statutory options, restricted stock unit awards and other equity incentive awards. As of ~~June 30, 2019, 1,800,000~~March 31, 2020, 1,229,132 shares remained available for grant under the Inducement Plan.

Table of Contents

2016 Employee Stock Purchase Plan

In February 2016, the Company adopted the 2016 Employee Stock Purchase Plan, (the “2016 ESPP”). The 2016 ESPP became effective on March 17, 2016. The maximum number of shares of common stock that may be issued under the 2016 ESPP was initially 800,000 shares and automatically increases on January 1 of each year, ending on and including January 1, 2026, by 1.0% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year; provided, however, the Board of Directors may act prior to the first day of any calendar year to provide that there will be no January 1 increase in the share reserve for such calendar year or that the increase in the share reserve for such calendar year will be a lesser number of shares of common stock. At March 31, 2020 there were 6,341,661 shares of common stock available for issuance under the 2016 ESPP.

The 2016 ESPP permits participants to purchase shares of the Company’s common stock through payroll deductions of up to 15% of their earnings. Unless otherwise determined by the administrator, the purchase price of the shares will be 85% of the lower of the fair market value of common stock on the first day of an offering or on the date of purchase. Participants may end their participation at any time and deductions not yet used in a purchase are refundable upon employment termination. The Company initiated its first 2016 ESPP offering period on August 1, 2019 and new offering periods occur every six months thereafter, each consisting of two purchase periods of six months in duration ending on or about January 31st and July 31st of each year. A participant may only be in one offering at a time. On February 1, 2020, there were 566,573 shares purchased in connection with the initial offering period. The 2016 ESPP contains an offering reset provision whereby if the fair market value of a share on offering date of an ongoing offering is less than or equal to the fair market value of a share on a new offering date, the ongoing offering will terminate immediately after the purchase date and rolls over to the new offering. During the three months ended March 31, 2020, 40 participants in the initial offering were automatically rolled over to the subsequent new offering as a result this reset provision and an incremental cost of less than $0.1 million.

The 2016 ESPP is considered compensatory for financial reporting purposes.

1997 Plan

On May 8, 1997, the Company adopted the 1997 Stock Option Plan (the “1997 Plan”), under which incentive stock options, ~~non‑qualified~~non-qualified stock options, and restricted stock awards may be granted to the Company’s employees and certain other persons in accordance with the 1997 Plan provisions. Approximately ~~7,076,638~~3,515,817 shares of the Company’s

~~Table of Contents~~

common stock underlying options have vested or are expected to vest under the 1997 Plan. Upon the effectiveness of the 2015 Plan, the Company no longer grants any awards under the 1997 ~~Plan.~~

PlanThe Company recognizes the cost of employee services received in exchange for awards of equity instruments, such as stock options, based on the fair value of those awards at the date of grant. The estimated fair value of stock options on the date of grant is amortized on a straight-line basis over the requisite service period for each separately vesting portion of the award for those awards with service conditions only. For awards that also contain performance conditions, expense is recognized beginning at the time the performance condition is considered probable of being met over the remaining vesting period..

~~10.Fair Value Measurements~~

The Company applies fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities that are required to be recorded at fair value, the Company considers the principal or most advantageous market in which the Company would transact and the market-based risk measurements or assumptions that market participants would use to price the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risk. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:

~~Level 1—Quoted prices for identical assets or liabilities in active markets.~~

Level 2—Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

~~Level 3—Inputs that are generally unobservable and typically reflect management’s estimate of assumptions that market participants would use in pricing the asset or liability.~~

The fair value of money market funds was derived from quoted prices in active markets for identical assets. The valuation technique used to measure the fair value of the Company’s debt instruments, all of which have counterparties with high credit ratings, were valued based on quoted market prices.

~~Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis~~

The Company has segregated its financial assets and liabilities that are measured at fair value on a recurring basis into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date in the table below. The inputs used in measuring the fair value of the Company’s money market funds included in cash equivalents are considered to be Level 1 in accordance with the three-tier fair value hierarchy. The fair market values are based on period-end statements supplied by the various banks and brokers that held the majority of the funds.

1816

Table of Contents

10.Fair Value Measurements

The following table represents the fair value hierarchy of the Company’s financial assets and liabilities measured at fair value on a recurring basis ~~as follows~~at March 31, 2020 and December 31, 2019 (in thousands):


	June 30, 2019								March 31, 2020
	Total		Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3
Assets
Money market funds	$	47,745	$	47,745	$	—	$	—
Money market funds⁽¹⁾									$	1,501	$	1,501	$	—	$	—
Commercial paper⁽¹⁾										4,797		—		4,797		—
Liabilities
Embedded features of the 2023 Notes	$	10,130	$	—	$	—	$	10,130	$	336	$	—	$	—	$	336
Embedded features of the 2025 Notes									$	15,560	$	—	$	15,560	$	—


	December 31, 2018								December 31, 2019
	Total		Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3
Assets
Money market funds	$	122,859	$	122,859	$	—	$	—
Money market funds⁽¹⁾									$	37,769	$	37,769	$	—	$	—
Commercial paper⁽¹⁾										13,870		—		13,870		—
Corporate bonds										6,256		—		6,256		—
Liabilities
Embedded features of the 2023 Notes	$	17,091	$	—	$	—	$	17,091	$	664	$	—	$	—	$	664
Embedded features of the 2025 Notes										25,543		—		25,543		—

⁽¹⁾ Classified as cash and cash equivalents due to their short-term maturity

The following table provides a reconciliation of the beginning and ending balances of items measured at fair value on a recurring basis that used significant unobservable inputs (Level 3) (in thousands):

Embedded

Features of the

2023 Notes
December 31, 2018

$
17,091
Change in fair value included in other income (expense)

(6,961)
June 30, 2019

$
10,130


	Embedded
	Features of the
	the Notes
December 31, 2019	$	664
Change in derivative liabilities		(328)
March 31, 2020	$	336

The ~~Company reviews the~~recurring Level 3 fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain financial instruments within the fair value hierarchy. The Company’s policy is to recognize transfers into and out of levels within the fair value hierarchy at the endmeasurements of the fiscal quarter in which the actual event or change in circumstances that caused the transfer occurs. There were no transfers between Level 1, Level 2, or Level 3 during the three and six months ended June 30, 2019 and 2018. When a determination is made to classify an asset or liability within Level 3, the determination is based upon the significanceembedded features of the 2023 Notes include the following significant unobservable inputs ~~to the overall fair value measurement.~~at March 31, 2020:


Unobservable Inputs	Assumptions
Risky (bond) rate	25.7	%
Stock price volatility	75.8 % - 99.1	%
Probabilities of make-whole provision	6.0 % - 83.1	%
Time period until maturity (yrs)	.25 - 2.84
Dividend yield	—	%

~~Financial Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis~~

~~The Company has no financial assets and liabilities that are measured at fair value on a non-recurring basis.~~

~~Non-Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis~~

~~The Company has no non-financial assets and liabilities that are measured at fair value on a recurring basis.~~

~~Non‑Financial Assets and Liabilities Measured at Fair Value on a Non‑Recurring Basis~~

The Company measures its long‑lived assets, including property and equipment, at fair value on a non‑recurring basis. These assets are recognized at fair value when they are deemed to be impaired. No such fair value impairment was recognized in the three and six months ended June 30, 2019 and 2018.

~~Table of Contents~~

11.Income Taxes

The Company has not recorded any tax provision or benefit for the ~~six~~three months ended ~~June 30, 2019~~March 31, 2020 or ~~June 30, 2018.~~March 31, 2019. The Company has provided a valuation allowance for the full amount of its net deferred tax assets since realization of any future benefit from deductible temporary differences, NOL carryforwards and research and development credits is not more-likely-than-not to be realized at ~~June 30, 2019~~March 31, 2020 and December 31, ~~2018.~~2019.

~~12. Related~~On March 27, 2020, Congress enacted the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”)

Table of Contents

to provide certain relief as a result of the COVID-19 pandemic. The enactment of the CARES Act did not result in any material adjustments to the Company’s income tax provision or net deferred tax assets for the three months ended March 31, 2020.

12.Related Party Transactions

Roche Holding A.G, through its ownership interests in Roche Finance Ltd (collectively, “Roche”), has a noncontrolling ownership interest in the Company. Revenue from Roche during the three months ended March 31, 2020 was less than $0.1 million. For the three months ended ~~June 30,~~March 31, 2019, ~~and 2018, revenues~~revenue from Roche ~~were $3.1 million and $3.1 million, respectively. For the six months ended June 30, 2019 and 2018, revenues from Roche were $5.3 million and $5.6 million, respectively.~~was $2.2 million. Amounts due from Roche aswere less than $0.1 million at March 31, 2020 and $7.1 million at December 31, 2019. At each of ~~June 30, 2019~~March 31, 2020 and December 31, ~~2018 were~~2019, the Company had committed replacement obligations under warranties of $0.6 million.

13.Subsequent Events

April 2020 Financings

PPP Loan

On April 22, 2020, the Company received $5.8 million in loan funding from the Paycheck Protection Program (“PPP”), established pursuant to the CARES Act and administered by the SBA. The unsecured loan (the “PPP Loan”) is evidenced by a promissory note of the Company dated April 21, 2020 (the “PPP Note”) in the principal amount of $5.8 million with Silicon Valley Bank (the “Bank”).

Under the terms of the PPP Note and the PPP Loan, interest accrues on the outstanding principal at the rate of 1.0% per annum. The term of the PPP Note is two years, though it may be payable sooner in connection with an event of default under the PPP Note. To the extent the loan amount is not forgiven under the PPP, the Company is obligated to make equal monthly payments of principal and interest, beginning seven months from the date of the PPP Note, until the maturity date.

The CARES Act and the PPP provide a mechanism for forgiveness of up to the full amount borrowed. Under the PPP, the Company may apply for forgiveness for all or a part of the PPP Loan. The amount of loan proceeds eligible for forgiveness is based on a formula that takes into account a number of factors, including the amount of loan proceeds used by the Company during the specified period after the loan origination for certain purposes including payroll costs, interest on certain mortgage obligations, rent payments on certain leases, and certain qualified utility payments, provided that at least 75% of the loan amount is used for eligible payroll costs; the employer maintaining or rehiring employees and maintaining salaries at certain levels; and other factors. Subject to the other requirements and limitations on loan forgiveness, only loan proceeds spent on payroll and other eligible costs during the specified period will qualify for forgiveness. As a result of the Company’s workforce reduction, the amount of forgiveness will correspondingly decrease, unless the Company is able to rehire impacted employees.

The PPP Note may be prepaid in part or in full, at any time, without penalty. The PPP Note provides for certain customary events of default, including (i) failing to make a payment when due under the PPP Note, (ii) failure to do anything required by the PPP Note or any other loan document, (iii) defaults of any other loan with the Bank, (iv) failure to disclose any material fact or make a materially false or misleading representation to the Bank or SBA, (v) default on any loan or agreement with another creditor, if the Bank believes the default may materially affect the Company’s ability to pay the PPP Note, (vi) failure to pay any taxes when due, (vii) becoming the subject of a proceeding under any bankruptcy or insolvency law, having a receiver or liquidator appointed for any part of the Company’s business or property, or making an assignment for the benefit of creditors, (viii) having any adverse change in financial condition or business operation that the Bank believes may materially affect the Company’s ability to pay the PPP Note, (ix) if the Company reorganizes, merges, consolidates, or otherwise changes ownership or business structure without the Bank’s prior written consent, or (x) becoming the subject of a civil or criminal action that the Bank believes may materially affect the Company’s ability to pay the PPP Note. Upon the occurrence of an event of default, the Bank has customary

Table of Contents

remedies and may, among other things, require immediate payment of all amounts owed under the PPP Note, collect all amounts owing from the Company, and file suit and obtain judgment against the Company.

Highbridge Loan Agreement

On April 21, 2020, the Company entered into a Loan and Security Agreement (the “Highbridge Loan Agreement”), with certain funds managed by Highbridge Capital Management, LLC, (“Highbridge”), as the lenders, together with the other lenders from time to time party thereto (“the Lenders”) and Wilmington Savings Fund Society, SCB, as collateral agent.

Pursuant to the Highbridge Loan Agreement, the Company may borrow up to an aggregate of $20.0 million in aggregate principal through the issuance and sale of First Lien Notes due October 2021 (the “First Lien Notes”). The Company received the first tranche of borrowing in the aggregate principal amount of $15.0 million on April 24, 2020. Under the terms of the Highbridge Loan Agreement, the Company may issue up to an additional $5.0 million in aggregate principal amount of First Lien Notes in a subsequent closing. In connection with the Highbridge Loan Agreement and ~~$6.3~~receipt of the first tranche of borrowing, the Company issued 1,500,000 shares of its common stock to the Lenders as a commitment fee.

The First Lien Notes are secured, senior obligations that bear interest at the annual rate of 12% or, at the Company’s election, payment in kind at an annual rate of 13%, payable monthly in arrears. The First Lien Notes will mature on October 24, 2021 (the “First Lien Maturity Date”) unless earlier repurchased, redeemed or converted in accordance with their terms. The obligations under the First Lien Notes are secured by substantially all the Company’s assets.

The Company has the right to prepay the First Lien Notes at any time, subject to a prepayment premium, which in certain circumstances the Company may elect to pay in its common stock, equal to the aggregate amount of interest payments through maturity. However, if the date of payment in cash of such prepayment premium is on or before August 22, 2020, the prepayment premium will be reduced by 25%.

Subject to certain conditions, if the Company retains or reinvests proceeds of an asset sale pursuant to the asset sale prepayment provisions in the Highbridge Loan Agreement, the Lenders shall be entitled to convert First Lien Notes and Holders (defined below) shall be entitled to convert Second Lien Notes in aggregate combined principal amount equal to 45% of such net proceeds retained or reinvested (together with any applicable prepayment premium) to the Company’s common stock at a price per share equal to 90% of the greater of (i) the daily volume weighted average of the price per share of the common stock, on the conversion date, or if the conversion date is not a trading date, the trading day immediately prior to the conversion date and (ii) $0.57 per share. This conversion option has a daily limit of $1.0 million ~~respectively.~~in aggregate converted principal (inclusive of principal amount of Second Lien Notes that are voluntarily converted by the Holders).

From and after a strategic transaction announcement (as defined in the form of First Lien Note), the Company may elect to convert up to $9.4 million in aggregate principal of the First Lien Notes to its common stock at a price per share equal to 90% of the greater of (i) the daily volume weighted average of the price per share of the common stock, on the conversion date, or if the conversion date is not a trading date, the trading day immediately prior to the conversion date and (ii) $0.57 per share of its common stock. This conversion option has a daily limit of $0.3 million in aggregate converted principal. If the Company or the Lenders elect to convert any of the First Lien Notes, the amount converted will be equal to the principal and unpaid accrued interest plus the applicable prepayment premium.

The Highbridge Loan Agreement contains customary terms and covenants, including without limitation: financial covenants, such as operating within an approved budget and maintaining a minimum cash balance; and negative covenants, such as limitations on indebtedness, liens, mergers, asset transfers, certain investing activities and other matters customarily restricted in such agreements. Most of these restrictions are subject to certain minimum thresholds and exceptions. The Highbridge Loan Agreement also contains customary events of default, after which the First Lien Notes may be due and payable immediately, including, without limitation, payment defaults, material inaccuracy of representations and warranties, covenant defaults, material adverse changes, bankruptcy and insolvency

Table of Contents

proceedings, cross-defaults to certain other agreements, judgments against the Company, and change of control, termination of any guaranty, governmental approvals, and lien priority.

Exchange Agreement with Highbridge

On April 21, 2020 the Company entered into a Note Purchase and Exchange Agreement (the “Exchange Agreement”) with certain funds managed by Highbridge providing for the exchange (the “Exchange”) of $24.0 million aggregate principal amount of the Company’s outstanding 2025 Notes for (i) $15.7 million aggregate principal amount of newly issued Second Lien Secured Notes due January 2022 (the “Second Lien Notes” and, together with the First Lien Notes, the “Senior Notes”), (ii) 11,026,086 shares of common stock, (iii) warrants (the “Warrants”) to purchase up to 4,500,000 shares of common stock at an exercise price of $0.66 per share, and (iv) $0.3 million in accrued and unpaid interest on the 2025 Notes being exchanged. The Exchange closed on April 24, 2020. The Warrants may be exercised in cash or on a cashless basis at any time through the three year anniversary of the issuance date.

The Second Lien Notes are secured, senior obligations of the Company, junior only to the First Lien Notes. Interest in cash at the annual rate of 7.5% or, at the Company’s option, payment in kind at an annual rate of 8.25%, on the Second Lien Notes will be payable monthly in arrears. The maturity date for the Second Lien Notes will be January 24, 2022 (the “Second Lien Maturity Date”), unless earlier repurchased, redeemed or converted in accordance with their terms. The obligations under the Second Lien Notes are secured by substantially all of the Company’s assets.

The Company will have the right to prepay the Second Lien Notes at any time, subject to a prepayment premium, which in certain circumstances the Company may elect to pay in common stock, equal to the aggregate amount of interest payments through maturity. However, if the date of payment in cash of such prepayment premium is on or before August 22, 2020, the prepayment premium will be reduced by 25%.

The holders of the Second Lien Notes (the “Holders”) will have the right to convert up to $7.0 million aggregate principal of the Second Lien Notes (together with any applicable prepayment premium) to common stock at a price per share equal to 90% of the greater of (i) the daily volume weighted average of the price per share of the common stock, on the conversion date, or if the conversion date is not a trading date, the trading day immediately prior to the conversion date and (ii) $0.57 per share. This conversion option has a daily limit of $1.0 million in aggregate converted principal (inclusive of principal amount of First Lien Notes that are voluntarily converted by the Lenders). Subject to certain conditions, if the Company retains or reinvests proceeds of an asset sale pursuant to the Asset Sale Prepayment Provisions in the Exchange Agreement, the Holders shall be entitled to convert additional Second Lien Notes and the Lenders shall be entitled to convert First Lien Notes in aggregate combined principal amount equal to 45% of such net proceeds retained or reinvested (together with any applicable prepayment premium). As of June 5, 2020, the Holders have converted $4.8 million for issuance of 10,502,291 shares of common stock.

From and after a strategic transaction announcement, the Company may elect to convert up to $8.7 million in aggregate principal of the Second Lien Notes to common stock at a price per share equal to 90% of the greater of (i) the daily volume weighted average of the price per share of the common stock, on the conversion date, or if the conversion date is not a trading date, the trading day immediately prior to the conversion date and (ii) $0.57 per share. This conversion option has a daily limit of $0.3 million in aggregate converted principal. If the Company or the Holders elect to convert any of the Second Lien Notes, the amount converted will be equal to the principal and unpaid accrued interest plus the applicable premium.

The Exchange Agreement contains customary terms and covenants, including without limitation: financial covenants, such as maintaining a minimum cash balance; and negative covenants, such as limitations on indebtedness, liens, mergers, asset transfers, certain investing activities and other matters customarily restricted in such agreements. Most of these restrictions are subject to certain minimum thresholds and exceptions. The Exchange Agreement also contains customary events of default, after which the Second Lien Notes may be due and payable immediately, without limitation, payment defaults, material inaccuracy of representations and warranties, covenant defaults, material adverse changes, bankruptcy and insolvency proceedings, cross-defaults to certain other agreements, judgments against us, and change of control, termination of any guaranty, governmental approvals, and lien priority.

Table of Contents

13~~.Subsequent Events~~

~~Convertible Notes~~

~~In July 2019,~~The Company may not issue shares of its common stock, net of the ~~Company issued $82.0 million in aggregate principal amount of 2025 Notes. The~~18,181,818 shares underlying the 2025 Notes ~~are general, unsecured, senior subordinated obligations~~exchanged in the Exchange, in excess of 19.99% of the common stock outstanding on April 21, 2020; this restriction is subject to removal upon approval by stockholders of the Company (the “Stockholder Approval”). The Company intends to seek the Stockholder Approval at the Company’s 2020 Annual Meeting of Stockholders on June 30, 2020.

Supplier and ~~bear interest~~Contract Manufacturer Obligations

As a result of the impact of the COVID-19 pandemic on the global healthcare community and the Company’s streamlined operational focus implemented at the end of the first quarter of 2020, the Company has been negotiating with certain of its major suppliers and contract manufacturers to pay for materials procured by these parties on the Company’s behalf or for costs incurred related to Eversense manufacturing activities that were paused or delayed by the Company. Some of these fees may also be dependent on whether the materials will expire prior to when the Company resumes production at normal operating levels, or if further delays in manufacturing occur. As of June 9, 2020, the Company expects to have to pay approximately $1.9 million for costs related to pausing manufacturing activities and $0.6 million if certain manufacturing timelines are not met within a ~~rate~~specified period. The Company will record any fees contingent upon future manufacturing in its consolidated financial statements if, and when, it is probable such obligations will become due. When the Company resumes manufacturing activity, some of 5.25% per year, payable semiannually in arrears on January 15 and July 15 of each year, beginning on January 15, 2020. The 2025 Notes will mature on January 15, 2025, unless earlier repurchased or converted.the amounts paid for materials may be credited back to the Company upon consumption.

The Company used $37.9 million of the net proceeds from the issuance of the 2025 Notes to repurchase $37.0 million aggregate principal amount of the Company’s outstanding 2023 Notes, at a purchase price equal to the principal amount thereof, plus accrued and unpaid interest thereon.

The 2025 Notes are convertible, at the option of the holders, into shares of the Company’s common stock, at an initial conversion rate of 757.5758 shares per $1,000 principal amount of the 2025 Notes (equivalent to an initial conversion price of approximately $1.32 per share).

The Company may redeem for cash all or part of the 2025 Notes, at its option, if (1) the last reported sale price of the Company’s common stock has been at least 150% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption and (2) a registration statement covering the resale of the shares of the Company’s common stock issuable upon conversion of the 2025 Notes is effective and available for use and is expected to remain effective and available for use during the redemption period as of the date of the redemption notice date. The redemption price will be equal to 100% of the principal amount of the 2025 Notes to be redeemed plus accrued and unpaid interest to, but excluding, the redemption date.

If the Company undergoes a fundamental change, holders may require the Company to repurchase for cash all or any portion of their 2025 Notes at a fundamental change repurchase price equal to 100% of the principal amount of the 2025 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. In addition, following a notice of redemption or certain corporate events that occur prior to the maturity date, the Company will, in certain circumstances, increase the conversion rate for a holder who elects to convert its 2025 Notes in connection with such notice of redemption or corporate event. In certain circumstances, the Company will be required to pay cash in lieu of delivering make whole shares unless the Company obtains stockholder approval to issue shares.

The 2025 Notes are guaranteed on a senior unsecured basis by the Company’s wholly-owned subsidiary, Senseonics, Incorporated, and may be guaranteed by certain future subsidiaries. The subsidiary guarantor is 100% owned, the guarantee is full and unconditional and joint and several and the parent company has no independent assets or operations and any subsidiaries of the parent company other than the subsidiary guarantor are minor.

~~Solar Loan Agreement~~

~~On July 16, 2019, the Company entered into the Solar Loan Agreement with Solar, as collateral agent, and the lenders from time to time party thereto (collectively, the “Solar Lenders”).~~

~~Pursuant to the Solar Loan Agreement, on July 25, 2019, the Company borrowed term loans in an aggregate principal amount of $45.0 million (the “Solar Term Loan”).~~ ~~The Company used $11.6 million~~ ~~of the Solar Term Loan to repay in full the Term Loans and terminate the Company’s existing credit facility with Oxford and SVB.~~

Table of Contents

Interest on the Solar Term Loan will be payable monthly at a floating annual rate of 6.50% plus the greater of (i) the rate per annum rate published by the Intercontinental Exchange Benchmark Administration Ltd. and (ii) 2.48%, provided that the minimum floor interest rate is 8.98%. The maturity date for the Solar Term Loan will be June 1, 2024 (the “Solar Maturity Date”). Commencing on August 1, 2021, the Company will be required to make monthly principal amortization payments; provided that the interest only period may be extended to (i) August 1, 2022 if the Company’s product revenue is greater than or equal to $40.0 million on a trailing six-month basis prior to the second anniversary of the effective date and (ii) August 1, 2023 if the Company’s product revenue is greater than or equal to $75.0 million on a trailing six-month basis after the achievement of the first extension.

The Company may elect to prepay the Solar Term Loan prior to the Solar Maturity Date subject to a prepayment fee equal to 3.00% if the prepayment occurs within one year of the effective date, 2.00% if the prepayment occurs during the second year following the effective date, and 1.00% if the prepayment occurs more than two years after the effective date and prior to the Solar Maturity Date.

The Solar Loan Agreement contains customary events of default, including bankruptcy, the failure to make payments when due, the occurrence of a material impairment on the Solar Lenders’ security interest over the collateral, a material adverse change, the occurrence of a default under certain other agreements entered into by the Company and its subsidiaries, the rendering of certain types of judgments against the Company and its subsidiaries, the revocation of certain government approvals, violation of covenants, and incorrectness of representations and warranties in any material respect. Upon the occurrence of an event of default, subject to specified cure periods, all amounts owed by the Company would begin to bear interest at a rate that is 5.00% above the rate effective immediately before the event of default, and may be declared immediately due and payable by the Solar Lenders.

The Solar Term Loan is secured by substantially all of the Company and its subsidiaries’ assets. The Solar Loan Agreement also contains specified financial covenants related to the Company’s liquidity and trailing six-month revenues.

The Solar Loan Agreement also contains certain restrictive covenants that limit the Company’s ability to incur additional indebtedness and liens, merge with other companies or consummate certain changes of control, acquire other companies, engage in new lines of business, make certain investments, pay dividends, transfer or dispose of assets, amend certain material agreements or enter into various specified transactions, as well as financial reporting requirements.

~~Warrants~~

In connection with the borrowing of the Solar Term Loan, the Company issued the Solar Lenders warrants to purchase an aggregate of 1,125,000 shares of its common stock with an exercise price of $1.20 per share (the “Solar Warrants”). The Solar Warrants are exercisable until July 25, 2029. The Solar Lenders also have the right to net exercise the Solar Warrants for shares of the Company’s common stock

~~Public Offering of Common Stock~~

In July, 2019, pursuant to an underwriting agreement with Jefferies LLC, the Company closed a follow-on public offering of 26,136,363 shares of its common stock at a price of $1.10 per share, which included the exercise in full by Jefferies LLC of its option to purchase up to 3,409,090 additional shares. The Company received aggregate gross proceeds of $28.7 million from the offering ~~before deducing underwriting discounts and offering expenses~~.

~~Table of Contents~~

ITEM 2: MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Certain statements contained in this Quarterly Report on Form 10-Q may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words or phrases “would be,” “will allow,” “intends to,” “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimate,” “project,” or similar expressions, or the negative of such words or phrases, are intended to identify “forward-looking statements.” We have based these forward-looking statements on our current expectations and projections about future events. Because such statements include risks, uncertainties, and ~~uncertainties,~~assumptions, including the duration and severity of the COVID-19 pandemic and its impact on our business and financial performance, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to these differences include those described below and elsewhere in this Quarterly Report on Form 10-Q, our Annual Report on Form 10-K, particularly in Part I – Item 1A, “Risk Factors,” and our other filings with the Securities and Exchange Commission. Statements made herein are as of the date of the filing of this Form 10-Q with the Securities and Exchange Commission and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim, any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited financial statements and related notes that appear in Item 1 of this Quarterly Report on Form 10-Q and with our audited financial statements and related notes for the year ended December 31, ~~2018,~~2019, which are included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March ~~15, 2019.~~16, 2020, as amended on April 28, 2020. Unless otherwise indicated or the context otherwise requires, all references in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” section to the "Company," "we," "our," "ours," "us" or similar terms refer to Senseonics Holdings, Inc. and its subsidiary.

Overview and Business Updates

We are a medical technology company focused on the ~~design,~~ development and commercialization of long-term, implantable continuous glucose monitoring, ~~products~~or CGM, systems to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Our ~~continuous glucose monitoring, or CGM, systems,~~ Eversense and Eversense XL ~~are reliable, long‑term, implantable~~ CGM systems ~~that we have~~are designed to continually and accurately measure glucose levels in people with diabetes via an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time glucose monitoring and management for a period of up to 90 and 180 days, respectively, as compared to ~~six~~seven to ~~fourteen~~14 days for non-implantable CGM systems.

The original Eversense CGM system received its CE mark in June 2016, which marked the first approval for the product to be sold within the European Economic Area. Subsequently, the extended life Eversense XL CGM system received its CE mark in September 2017 and is currently available ~~CGM systems. We believe Eversense and Eversense XL will provide people with diabetes with a more convenient method to monitor their glucose levels~~ in comparison with the traditional method of self‑monitoring of blood glucose, or SMBG, as well as currently available CGM systems. In our U.S. pivotal clinical trial, we observed that Eversense measured glucose levels over 90 days with a degree of accuracy superior to that of other currently available CGM systems. Our Eversense and Eversense XL systems are currently approved for saleselect markets in Europe, the Middle East, and Africa, ~~(EMEA)~~or EMEA. In June 2018, the U.S. Food and ~~our~~Drug Administration, or FDA, approved the Eversense CGM system and it is currently available throughout the United States. In June 2019, we received FDA approval for the non-adjunctive indication (dosing claim) for the Eversense system. With this approval and the availability of a new app in December 2019, the Eversense system ~~is currently approved for sale~~can be used as a therapeutic CGM in the United ~~States.~~States to replace fingerstick blood glucose measurement to make treatment decisions, including insulin dosing.

~~Recent Developments~~

~~In July 2019, we~~ ~~closed a follow-on public offering~~Our net revenues are derived from sales of ~~26,136,363 shares of our common stock at a price of $1.10 per share,~~the Eversense CGM system which ~~included~~is sold in two separate kits: the ~~exercise in full by~~disposable Eversense Sensor Pack which includes the ~~underwriter of its option to purchase up to 3,409,090 additional shares. We received aggregate gross proceeds of $28.7 million from~~sensor, insertion tool, and adhesive patches, and the ~~offering~~ ~~before deducing underwriting discounts~~durable Eversense Smart Transmitter Pack which includes the transmitter and ~~offering expenses~~.charger.

~~On July 25, 2019, we issued $82.0 million aggregate principal amount~~We sell directly to our network of ~~our 5.25% Convertible Senior Notes due 2025, or~~distributors and strategic fulfillment partners, who provide the ~~2025 Notes,~~Eversense system to ~~Jefferies LLC as~~healthcare providers and patients through a prescribed request and invoice insurance payors for reimbursement. Sales of the ~~initial purchaser, or the Initial Purchaser, who subsequently resold the 2025 Notes to qualified institutional buyers, or the Notes Offering, in reliance~~Eversense system are widely dependent on the ~~exemption~~ability of patients to obtain coverage and adequate reimbursement from ~~registration provided by Rule 144A under~~third-party payors or government agencies. We leverage and target regions where we have coverage decisions for patient device use and provider insertion and removal procedure payment. During the ~~Securities Act of 1933, as amended.~~

quarter

2322

Table of Contents

ended March 31, 2020, we received positive payor coverage decisions from Cigna Corporation, who has more than 17 million medical customers and offers a Medicare Advantage plan in 17 states and Washington DC. In May 2020, we received positive payor coverage by additional Blue Cross and Blue Shield plans, and announced local coverage determinations (LCD) proposals for implantable therapeutic CGMs such as Eversense by three Medicare Administrative Contractors to enable Eversense to be used by Medicare beneficiaries as a Part B physician service.

~~We used $37.9 million~~

Development and Commercialization of Eversense

In December 2018, we initiated the PROMISE pivotal clinical trial to evaluate the safety and accuracy of Eversense XL for a period of up to 180 days in the United States. On September 30, 2019, we completed enrollment of the ~~net proceeds~~PROMISE trial and had our last patient complete their 180-day visit during the first quarter of 2020. We plan to analyze data from the ~~Notes Offering~~PROMISE trial, and if the data from the PROMISE trial is positive, we intend to ~~repurchase $37.0 million aggregate principal amount our outstanding 5.25% convertible senior subordinated notes due 2023, or~~use the ~~2023 Notes, at~~data in a ~~purchase price equal~~regulatory submission to the ~~principal amount thereof, plus accrued~~FDA in late summer of 2020 to potentially expand the Eversense system use for up to 180 days in the United States. If approved by the FDA, Eversense XL will double sensor duration of Eversense in the United States, with half of the insertion and ~~unpaid interest thereon.~~removal procedures required, and will provide more than 12 times longer sensor duration than other CGM systems available in the United States. However, shelter-in-place orders and other impacts from the coronavirus, or COVID-19, pandemic could alter or delay the timing of response by the FDA regarding our submission. We also intend to use data from the PROMISE trial, if positive, to support a regulatory submission to the FDA for an integrated, or iCGM, designation in the second half of 2020. This would allow Eversense to integrate with other compatible medical devices and electronic interfaces, such as automated insulin dosing systems, insulin pumps, and blood glucose meters. On February 26, 2020, we announced that the FDA approved a subgroup of PROMISE trial participants to continue for a total of 365 days to gather feasibility data on the safety and accuracy of a 365-day sensor. This sub-set of more than 35 participants who all had sensors with the modified chemistry will be left undisturbed for 365 days with the goal of measuring accuracy and longevity over the full 365 days.

In April 2020, we announced that we received regulatory approval in Europe such that the Eversense XL is no longer contraindicated for MRI, which means the sensor does not need to be removed from under the skin during MRI scanning. We had previously obtained this indication for Eversense in the United States in 2019. This MRI approval is a first for the CGM category as all other sensors are required to be removed during an MRI scan.

Repayment of Solar Loan

On ~~July 16, 2019,~~March 22, 2020, we ~~entered into an~~and Solar Capital Ltd., or Solar, terminated our Loan and Security Agreement, dated as of July 16, 2019, or the Solar Loan ~~Agreement, with Solar Capital, Ltd. a Maryland corporation, or Solar, as collateral agent, and the lenders from time~~Agreement. As previously disclosed in our Annual Report on Form 10-K, we expected to ~~time party thereto, or collectively, the Lenders.~~

~~Following~~default on our ~~closing of the Notes Offering, we borrowed an aggregate principal amount of $45.0 million~~obligations under the Solar Loan Agreement orand were seeking a waiver from Solar of any default under the Solar ~~Term Loan. We used $11.6 million of~~Loan Agreement. Following discussions with Solar, we were unable to negotiate such a waiver and, as a result, it was determined to terminate the Solar ~~Term~~ Loan to terminate our existing Amended and Restated Loan and Security Agreement with Oxford Finance LLC, or Oxford, and Silicon Valley Bank, or SVB, and repay in full outstanding borrowings thereunder, or the Oxford/SVB Term Loans.Agreement.

In ~~addition,~~connection with the termination, we paid $48.5 million representing all amounts outstanding under the Solar Loan Agreement, including the principal amount and interest of the loans, a payoff fee of 6.45% of the loans outstanding, a prepayment premium of 3.0% of the loans outstanding and other obligations owed to Solar thereunder. We issued warrants in connection with the ~~borrowing of the~~ Solar ~~Term~~ Loan ~~we issued the Lenders warrants~~Agreement to purchase an aggregate of 1,125,000 shares of our common stock with an exercise price of $1.20 per share, ~~or the Solar Warrants. The Solar Warrants~~which are exercisable until July 25, 2029.

~~European Commercialization~~

We recorded a loss on the extinguishment of ~~Eversense~~

In September 2015, we entered into a distribution agreement with Rubin Medical, or Rubin, pursuant to which we granted Rubin the exclusive right to market, sell and distribute Eversense in Sweden, Norway and Denmark through September 2020. Rubin markets and sells medical products for diabetes treatmentdebt in the ~~Scandinavian region, including~~amount of $4.5 million reflecting the difference between the repayment amount, excluding interest accrued and due, and the carrying value of the principal balance, accrued interest, unamortized debt issuance costs and unaccreted prepayment fee at March 22, 2020 in other income (expense) in our accompanying unaudited consolidated statement of operations and comprehensive loss during the three months ended March 31, 2020.

COVID-19

On January 30, 2020, the World Health Organization, or the WHO, announced a global health emergency because of a new strain of coronavirus, or COVID-19, and the risks to the international community as the ~~exclusive Scandinavian distributor~~virus spreads

Table of Contents

globally. On March 11, 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally. In response to the pandemic, many states and jurisdictions have issued stay-at-home orders and other measures aimed at slowing the spread of the coronavirus. The state of Maryland, where we are headquartered, has been affected by COVID-19. The Governor of Maryland has issued an order closing all non-essential businesses, which took effect on March 23, 2020. Substantially all of our workforce is currently working from home either all or substantially all of the time. Additionally, because our sensor requires an in-clinic procedure, we have seen a reduction in access to clinics and sensor insertions during the outbreak. It is difficult to predict the longevity and severity COVID-19 will have on a smaller business like ours still in the early stages of commercialization.

Net Revenue Impact

As a result of the COVID-19 pandemic, redistribution of country-specific government funding to COVID-19 efforts, and overall excess inventory at our distributors, our net revenue for the ~~insulin pump manufacturer Tandem Corporation.~~three months ended March 31, 2020 was significantly lower than expected and we are uncertain as to the longevity or severity of the impact on our future sales. Under ~~the agreement, Rubin is obligated to purchase from us specified minimum volumes of Eversense components at pre-determined prices.~~

~~In May 2016, we entered into a~~our exclusive distribution agreement with Roche Diagnostics International AG and Roche Diabetes Care GmbH, ~~together referred to as~~or collectively, Roche, ~~pursuant to which~~ we have granted Roche the exclusive right to market, sell and distribute Eversense in ~~Germany, Italy and~~ the Netherlands. Under the agreement, Roche is obligated to purchase from us specified minimum volumes of Eversense components at pre-determined prices. We began distributing Eversense through Roche in Germany in September 2016 and in Italy and the Netherlands in the fourth quarter of 2016. In November 2016, we entered into an amendment to the distribution agreement with Roche granting Roche the exclusive right to market, sell and distribute Eversense in Europe, the Middle East and Africa,EMEA, excluding ~~Sweden, Norway, Denmark, Finland~~Scandinavia and Israel. In ~~January 2019, we entered into an additional amendment to the distribution agreement with~~addition, Roche ~~to extend the agreement through January 31, 2021. Pursuant to the amendment to the agreement, Roche~~ has agreed to certain purchase levels of Eversense systems and pricing terms through the extended term of the agreement. In addition, under the amendment, Roche’s role as the exclusive distributor of Eversense was expanded to provide Roche with exclusive distribution rights in 17 additional countries, including Brazil, Russia, India and China, as well as select markets in the Asia Pacific and Latin American regions. ~~To date,~~Roche did not place any commercial sales orders in accordance with their distribution agreement during the three months ended March 31, 2020. We provided one-time COVID-19 pandemic relief concessions to some of our customers in the United States for allowances up to a specified amount of first quarter purchases if they are unable to sell through Eversense and related components on hand prior to expiry, which we ~~have begun distributing~~expect to occur in the third and fourth quarters of 2020. Our net revenues and corresponding accounts receivables were reduced for these allowances at March 31, 2020. We are continuing our Eversense ~~in an aggregate of 15 European countries through Rubin and Roche.~~Bridge Program for existing patients on Eversense.

~~In September 2017,~~Inventory

As a result of significant changes and uncertainty regarding our forecasted demand and related expiry concerns, we ~~received~~impaired $15.0 million of inventory and related assets at March 31, 2020 with a corresponding charge to cost of sales in our unaudited consolidated results of operations and comprehensive loss for the ~~CE mark~~three months ended March 31, 2020. We will continue to assess our inventory and supplier related assets for recoverability if conditions materially change or worsen.

Long-lived Assets

We reviewed our long-lived assets, including property and equipment and right-of-use assets, for recoverability, which resulted in a loss on disposal of property and equipment in the amount of $0.2 million for the three months ended March 31, 2020, which we recorded to other income (expense) in our unaudited consolidated statement of operations and comprehensive loss. The impairment mostly related to the uncertainty of conducting validation efforts to be able to place new manufacturing equipment into service.

The ultimate severity and longevity of the COVID-19 pandemic is unknown, and therefore, it is possible that impairments could be identified in future periods, and such amounts could be material.

Streamlined Operational Focus

As a result of the COVID-19 pandemic’s disruption to our operations, suppliers, employees, and the healthcare community in which we sell to and support, and our limited cash on hand at March 31, 2020 after repayment of the Solar Loan Agreement, we made significant reductions in our cost structure and operations to improve cash flow and generate future expenditure savings to ensure the long-term success of Eversense. Specifically, we temporarily suspended commercial sales and marketing of the Eversense CGM system in the United States to new patients to solely focus our resources on supporting existing users and the development and regulatory submission of our Eversense XL ~~which is indicated~~CGM system for ~~a sensor life of~~use for up to 180 ~~days. Eversense XL began commercialization in Europe in the fourth quarter of 2017. All such commercialization and marketing activities remain subject to applicable government approvals.~~

~~United States Development and Commercialization of Eversense~~

~~In 2016, we completed our PRECISE II pivotal clinical trial in the United States. This trial, which was fully enrolled with 90 subjects, was conducted at eight sites~~days in the United States. In ~~the trial,~~connection with these actions, on March 26, 2020, we ~~measured the accuracy~~reduced our workforce by approximately 60%, over half of Eversense measurements through 90 days after insertion. We also assessed safety through 90 days after insertion or through sensor removal. In the trial, we observed a mean absolute relative difference, or MARD, of 8.5% utilizing two calibration points for Eversense across the 40-400 mg/dL range when compared to YSI blood reference values during the 90-day continuous wear period. Based on the data from this trial, in October 2016 we submitted a pre-market approval, or PMA, application to the FDA to market Eversense in the United States for 90-day use. On June 21, 2018, we receivedwhich were sales personnel. Associated one-time employee

Table of Contents

~~PMA approval~~termination benefit costs in the amount of $1.6 million were accrued and recorded in our accompanying unaudited consolidated financial statements as of March 31, 2020.

Exploring Strategic Alternatives

Our Board of Directors has been and is continuing to explore potential strategic alternatives to enhance stakeholder value and we have been in discussions with new financing sources.

April 2020 Financings

On April 22, 2020, we received $5.8 million in loan funding from the ~~FDA~~Paycheck Protection Program, or PPP, established pursuant to the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, and administered by the U.S. Small Business Administration, or SBA, to support payroll, rent, and utilities incurred during a defined period.

On April 24, 2020, we received $15.0 million through the issuance and sale of First Lien Secured Notes due October 2021, or the First Lien Notes, pursuant to a Loan and Security Agreement, or the Highbridge Loan Agreement, with certain funds managed by Highbridge Capital Management, LLC, or Highbridge, as the lenders, together with the other lenders from time to time party thereto, or the Lenders, and Wilmington Savings Fund Society, SCB, as collateral agent. Under the terms of the Highbridge Loan Agreement, we may issue up to an additional $5.0 million in aggregate principal amount of First Lien Notes in a subsequent closing. In connection with the Highbridge Loan Agreement, we also issued 1,500,000 shares of common stock to the Lenders as a commitment fee.

The Lenders were current holders of $24.0 million of our convertible senior subordinated notes due 2025, or the 2025 Notes. In connection with the Highbridge Loan agreement, we entered into a Note and Purchase Exchange Agreement with the Lenders, pursuant to which those 2025 Notes were exchanged for (i) $15.7 million aggregate principal amount of newly issued Second Lien Secured Notes due January 2022, or the Second Lien Notes, (ii) 11,026,086 shares of common stock, (iii) warrants to purchase up to 4,500,000 shares of our common stock at an exercise price of $0.66 per share, and (iv) $0.3 million in accrued and unpaid interest on the 2025 Notes being exchanged.

These credit facilities are further described under Liquidity and Capital Resources.

Going Concern

In December 2018, we initiated the PROMISE pivotal clinical trial to evaluate the safety and accuracy of Eversense for a period of up to 180 days in the United States. We plan to enroll over 200 subjects in this trial at up to 15 clinical sites. If the datanext twelve months from the ~~PROMISE trial~~date of this Quarterly Report on Form 10-Q. Our ability to generate enough cash to meet our streamlined working capital requirements is ~~positive, we intend~~dependent on our ability to ~~use the data in a regulatory submission~~achieve additional capital sources and favorable outcomes from potential strategic alternatives. New financings may not be available to ~~the FDA to expand the Eversense system use to 180 days in the United States. We expect to report topline data from the PROMISE trial in the first half of 2020.~~

In March 2019, we launched a patient access program, the Eversense Bridge Program, to assist those patients who do not have insurance coverage for Eversense, or whose insurance is denied or insufficient. Pursuant to this program, we are providing financial assistance to eligible patients purchasing Eversense to enable more patients to access the Eversense system. The amount of assistance that we provide dependsus on a patient’s insurance coverage. The program establishes maximum limits per patient and excludes certain patients as ineligible, including government-insured patients and residents of certain states. Although this program has just recently begun, we already see stimulated interest and activity across patients and providers. The program provides opportunities to engage both regional and national payors, which we expect will lead to additional positive payor coverage decisions for the Eversense system.

In June 2019, we received FDA approval for the non-adjunctive indication (dosing claim) for the Eversense system. With this approval, Eversense system can now be used as a therapeutic CGM to replace fingerstick blood glucose measurement for dosing decisions. We plan to roll out the Eversense system with this expanded indication in the United States starting in the second half of 2019.

We have never been profitable and our net losses were $31.1 million and $32.5 million for three months ended June 30, 2019 and 2018, respectively, and $61.2 million and $54.8 million for the six months ended June 30, 2019 and 2018, respectively. As of June 30, 2019, our accumulated deficit totaled $418.2 million, primarily as a result of expenses incurred in connection with our research and development programs and from general and administrative expenses associated with our operations. We expect to continue to incur significant expenses and increasing operations and net losses for the foreseeable future.

We have incurred and expect to continue to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. In addition, we expect to continue incurring expenses associated with the research and development of our other products and maintaining, expanding and protecting our intellectual property portfolio and seeking regulatory approvals in other jurisdictions. Furthermore, we expect to continue to incur additional costs associated with operating as a public company, including significant legal, accounting, investor relations and other expenses that we did not incur as a private company. We will need to obtain substantial additional funding in connection with our continuing operations through debt financings, public or private equity or other sources, which may include collaborations with third parties. However, we may be unable to raise additional funds when needed on favorablecommercially acceptable terms, or at ~~all. Our failure to raise such capital as~~all, and ~~when needed would have a negative impact on~~may be impacted by our financial condition and our ability to successfully commercialize Eversense and develop and commercialize future products and our ability to pursue our business strategy. We will need to generate significant revenues to achieve profitability, and we may never do so.current debt covenants.

Financial Overview

Revenue

~~During three and six months ended June 30, 2019, we generated~~We generate product revenue from sales of the Eversense ~~and Eversense XL~~ system ~~in Europe pursuant to distribution agreements with Roche and Rubin, and from sales of the Eversense system in the United States. We recognize revenue upon the sales of Eversense systems~~ and related components and supplies at a fixed price to ~~our~~third-party distributors ~~for sales outside of~~in the ~~United States~~European Union and to ~~our~~a network of strategic fulfillment partners ~~for sales~~ in the United States, or collectively, Customers, who then resell the products to health care providers and patients. We are paid for our sales directly to the Customers, regardless of whether ~~these customers~~or not the Customers resell ~~those~~the products to health care providers and patients. Under the terms of our distribution ~~agreements~~agreement with Roche, ~~and Rubin, these distributors are~~Roche is contractually obligated to make certain

Table of Contents

~~make certain~~ minimum purchases of Eversense systems from us and, accordingly, the revenue we recognize for any given period is not necessarily indicative of the level of sales to end users for that, or any other, period. ~~We expect that our revenue~~

Revenue from ~~both European and U.S.~~ product sales ~~will continue to increase~~is recognized at a point in time when the Customers obtain control of our product based upon the delivery terms as defined in the ~~remainder~~contract at an amount that reflects the consideration which we expect to receive in exchange for the product. Contracts with our distributors contain performance obligations, mostly for the supply of goods, and is typically satisfied upon transfer of control of the product. Customer contracts do include the right to return.

We recognize revenue only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur in a future period. Our contracts may contain some form of variable consideration such as prompt-pay discounts or tier-volume price discounts. Variable consideration, including reimbursements paid by us to our Customers in accordance with the Eversense Bridge Program initiated in March 2019 and ~~future years~~to a lesser extent, other discounts, is treated as a reduction in revenue when the product sale is recognized. Depending on the variable consideration, we ~~continue our commercialization efforts. If we fail to successfully commercialize or are otherwise unable to complete~~develop estimates for the ~~development~~expected value based on the terms of ~~Eversense, our ability to generate future revenue,~~the agreements, historical data, insurance payor mix, reimbursement rates, and ~~our results of operations and financial position, will be adversely affected.~~

~~Under~~market conditions. In connection with the Eversense Bridge Program, we ~~account~~reimburse participating Customers an amount up to a fixed maximum for ~~reimbursements to~~ the ~~patient as a reduction of revenue~~difference in the ~~period in~~cost of the Eversense System and what they collect from insurance payors and the patient’s fee of $99. Our Customers are responsible for confirming patient insurance coverage, obtaining pre-authorizations, determining eligibility, and continuously provide us with data regarding which patient orders are under the ~~corresponding gross revenue is recognized. For~~program and which are not. We use this data, along with actual reimbursements that have been validated to patient claims, to support our expected reimbursement estimates. Estimated reimbursement payments for product shipped to ~~our customers~~Customers but not ~~sold~~provided to a patient within the same reporting period ~~we estimate the amount of reimbursement based on our historical experience~~are recorded within accrued expenses and ~~record as an accrued expense within~~other current liabilities in ~~our~~the accompanying consolidated balance sheets. Because of our limited experience with the Eversense Bridge Program, ~~as of June 30, 2019,~~ our ~~estimated reimbursement rates with respect to such shipped, but unsold, products~~estimates used in determining the variable consideration on a sale transaction could change in future periods, and such changes could be material.

~~Cost~~Contract assets consist of ~~Sales~~

~~We utilize~~trade receivables from Customers and contract ~~manufacturers~~liabilities consist of amounts due to ~~produce Eversense. Cost of sales consists primarily of~~ the ~~components of~~Customers in connection with the Eversense Bridge Program, classified as patient access and ~~assembly, as well as reserves~~incentive programs within accrued liabilities on the accompanying unaudited consolidated balance sheets. Trade receivables for warranty costs and any obsolete inventory. Other cost of sales includes distribution-related expenses such as logistics and shipping costs of Eversense to Roche and Rubin for distribution in various regions in EMEA and costs associated with distribution through our strategic fulfillment partners in the United States. We calculate gross margin as revenue less costs of sales divided by revenue. We expect our overall gross margin to improve over the long term, as our sales increase and we have more opportunities to leverage our costs over larger production volumes. However, our gross margins may fluctuate from period to period.

~~Sales and Marketing~~

Sales and marketing expenses consist primarily of salaries, commissions, and other related costs, including stock-based compensation, for personnel who perform sales, marketing, and customer support functions. Other significant costs include marketing programs, educational and promotional materials, consultants, and tradeshow expenses.

~~We anticipate that our sales and marketing expenses will increase in the future with appropriate investment as we continue to expand our commercialization of Eversense both~~customers in the United States ~~and Europe.~~are recorded at net realizable value, which is generally the contractual price but may be net of anticipated prompt-pay or promotional discounts.

~~Research~~Concentration of Revenue and ~~Development~~Customers

~~Research~~For the three months ended March 31, 2020 and ~~development expenses consist~~March 31, 2019, we derived less than 1% and 59%, respectively, of expenses incurred in performing research and development activities in developing Eversense, including clinical trials and feasibility studies, and partnerships for strategic initiatives including insulin delivery and new indications. Research and development expenses include compensation and benefits for research and development employees including stock‑based compensation, cost of laboratory supplies, clinical trial and related clinical manufacturing expenses, costs related to regulatory operations, fees paid to contract research organizations and other consultants, and other outside expenses. Research and development costs are expensed as incurred.our net revenues from one customer, Roche.

~~We have incurred significant research~~Revenue by Geographic Region

The following table sets forth net revenue derived from our two primary geographical markets, the United States and ~~development expenses from inception, with the substantial majority~~outside of the ~~expenses spent~~United States, based on the ~~development of Eversense. We expect~~geographic location to ~~continue to commit significant resources to continue to develop future~~which we deliver the product, ~~enhancements for Eversense and to conduct ongoing and future clinical trials. We expect that our overall research and development expenses will increase~~ for the ~~PROMISE~~three months ended March 31, 2020 and ~~other studies in support of future product enhancements.~~2019:

~~General and Administrative~~


	March 31, 2020				March 31, 2019
			%				%
(Dollars in thousands)	Amount		of Total		Amount		of Total
Revenue, net:
Outside of the United States	$	12	33.3	%	$	2,607	76.2	%
United States		24	66.7			816	23.8
Total	$	36	100.0	%	$	3,423	100.0	%

General and administrative expenses consist primarily of salaries and other related costs, including stock‑based compensation, for personnel in our executive, finance, accounting, business development, and human resources

Table of Contents

~~functions. Other significant costs include information technology, facility costs, legal fees relating to patent and corporate matters and fees for accounting and consulting services.~~

Accounts Receivable

~~Our general~~Accounts receivable consist of amounts due from our Customers and ~~administrative expenses have increased,~~are recorded at net realizable value, which may include an allowance for doubtful accounts at the time potential collection risk is identified or for promotional or prompt-pay discounts offered. We provided one-time COVID-19 pandemic relief concessions to some of our customers in the United States for allowances up to a specified amount of first quarter purchases if they are unable to sell through Eversense and related components on hand prior to expiry, which we expect ~~them~~ to ~~continue to increase at a lower rate~~occur in the ~~future~~third and ~~to decline as~~fourth quarters of 2020. Our net revenues and corresponding accounts receivables were reduced by $1.2 million for these allowances at March 31, 2020. We do not have a ~~percentage~~history of ~~revenue. These increases include increased costs related to the hiring of additional personnel~~collectability concerns and increased fees to outside consultants, lawyers and accountants as well as expenses related to maintaining compliance with NYSE American listing rules and SEC requirements, insurance, and investor relations costs. These expenses may further increase when wethere have been no ~~longer qualify as an “emerging growth company” under the Jumpstart Our Business Startups Act of 2012,~~provisions for uncollectible accounts recorded against accounts receivable at March 31, 2020 or ~~the JOBS Act, which will require us to comply with certain reporting requirements from which we are currently exempt. We will no longer qualify as an “emerging growth company” effective~~ December 31, 2019.

~~Other Income (Expense), Net~~

~~Interest income consists~~Use of interest earned on our cash equivalents. Interest expense primarily has consisted of interest expense on our convertible senior subordinated notes, and our obligations under the Amended and Restated Loan and Security Agreement with Oxford and SVB. This interest expense primarily consisted of contractual interest on the outstanding debt balances and amortization of debt discounts. During the six months ended June 30, 2018, we issued an aggregate of $53.0 million in aggregate principal amount of convertible senior subordinated notes, or the 2023 Notes. We bifurcated the embedded conversion option of the 2023 Notes, along with the interest make-whole provision and make-whole fundamental change provision, and recorded the embedded conversion option as a derivative liability in our consolidated balance sheets. This embedded derivate instrument is remeasured at the end of each reporting period with changes in fair value recorded to change in fair value of derivative liability in our consolidated results of operations.

~~Results of Operations~~

~~Comparison of the three months ended June 30, 2019 and 2018~~Estimates

The ~~following table sets forth~~preparation of our consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenue and expenses during the reporting period. In our accompanying unaudited consolidated financial statements, estimates are used for, but not limited to, stock-based compensation, recoverability of long-lived assets, deferred taxes and valuation allowances, derivative liabilities, obsolete inventory, warranty obligations, variable consideration related to revenue, depreciable lives of property and equipment, and accruals for clinical study costs, which are accrued based on estimates of work performed under contract. We considered COVID-19 related impacts to our estimates, as appropriate, within our unaudited consolidated financial statements and there may be changes to those estimates in future periods due to the uncertainties surrounding the severity and duration of the COVID-19 pandemic. Actual results ~~of operations for the three months ended June 30, 2019 and 2018 (in thousands):~~could differ from those estimates; however, we do not believe that such differences would be material.

Three Months Ended

June 30,

Period-to-

2019

2018

Period Change

(unaudited)

Revenue, net

$
1,475

$
553

$
922

Revenue, net - related parties

3,132

3,070

62

Cost of sales

9,160

3,839

5,321

Gross profit

(4,553)

(216)

(4,337)

Expenses:

Sales and marketing expenses

14,179

6,177

8,002

Research and development expenses

10,504

8,289

2,215

General and administrative expenses

5,417

5,382

35

Operating loss

(34,653)

(20,064)

(14,589)

Other income (expense), net:

Interest income

410

241

169

Interest expense

(1,965)

(2,236)

271

Change in fair value of derivative liability

4,889

(10,166)

15,055

Other income (expense)

245

(271)

516

Total other income (expense), net

3,579

(12,432)

16,011

Net loss

$
(31,074)

$
(32,496)

$
1,422

Recent Accounting Pronouncements

Recently Adopted

In August 2018, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement, which eliminates, adds and modifies certain disclosure requirements on fair value measurements. The new standard includes additional disclosure requirements regarding the range and weighted average to develop significant unobservable inputs within Level 3 fair value measurements. We adopted this on its effective date, January 1, 2020 and did not have a material impact on the consolidated financial statements and related disclosures.

Not Yet Adopted

In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses: Measurement of Credit Losses on Financial Instruments, which requires entities to record expected credit losses for certain financial instruments, including trade receivables, as an allowance that reflects the entity's current estimate of credit losses expected to be incurred. For available-for-sale debt securities in unrealized loss positions, the new standard requires allowances to be recorded instead of reducing the amortized cost of the investment. We do not currently hold or plan to invest in available-for-sale securities and have not historically experienced collection issues or bad debts with trade receivables. Accordingly, we do not expect this to have a significant impact on our consolidated financial statements and related disclosures at this time. We will adopt this guidance on its effective date for smaller reporting companies, January 1, 2023.

In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes, which is intended to simplify various aspects of the income tax accounting guidance, including requirements such as tax basis step-up in goodwill obtained in a transaction that is not a business combination, ownership changes in investments, and interim-period accounting for enacted changes in tax law. ASU 2019-12 is effective for public business entities for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years, and early adoption is permitted. We are currently evaluating the impact that this guidance will have on our consolidated financial statements.

Table of Contents

Results of Operations

Comparison of the three months ended March 31, 2020 and 2019

The following table sets forth our results of operations for the three months ended March 31, 2020 and 2019 (in thousands):


	Three Months Ended
	March 31,				Period-to-
	2020		2019		Period Change
	(unaudited)
Revenue, net	$	31	$	1,243	$	(1,212)
Revenue, net - related parties		5		2,180		(2,175)
Total revenue		36		3,423		(3,387)
Cost of sales		19,670		6,733		12,937
Gross profit		(19,634)		(3,310)		(16,324)

Expenses:
Sales and marketing expenses		11,145		12,834		(1,689)
Research and development expenses		7,362		7,108		254
General and administrative expenses		5,690		6,516		(826)
Operating loss		(43,831)		(29,768)		(14,063)
Other income, net:
Interest income		209		627		(418)
Loss on extinguishment of debt		(4,546)		—		(4,546)
Interest expense		(4,373)		(2,034)		(2,339)
Change in fair value of derivative liabilities		10,311		2,072		8,239
Other expense		(363)		(262)		(101)
Total other income, net		1,238		403		835
Net loss	$	(42,593)	$	(29,365)	$	(13,228)

Revenue, net

Our net ~~revenues increased~~revenue decreased $3.4 million to ~~$4.6~~less than $0.1 million for the three months ended ~~June 30, 2019,~~March 31, 2020, compared to ~~$3.6~~$3.4 million for the three months ended ~~June 30, 2018.~~March 31, 2019. This ~~increase~~decrease was ~~primarily due~~a result of deferral of sales orders by Roche in the first quarter of 2020, and reductions for significant one-time COVID-19 relief concessions and allowances up to ~~sales~~a specified amount of ~~Eversense~~first quarter purchases provided to some of our larger customers in the United States ~~in the three months ended June 30, 2019 following our U.S. launch in July 2018, partially offset by gross to net reductions to revenue~~and costs for the Eversense Bridge Program.

Cost of sales

Our cost of sales increased $12.9 million to ~~$9.2~~$19.7 million for the three months ended ~~June 30, 2019,~~March 31, 2020, compared to ~~$3.8~~$6.7 million for the three months ended ~~June 30, 2018.~~March 31, 2019. The increase was primarily due to ~~$1.9 million of U.S. sales, a $1.3 million increase in warranty expense, a $2.0 million increase in~~ impairment charges, scrap and write-offs of $16.3 million for ~~obsolete~~ inventory ~~associated with product design~~and related assets due to uncertainty in demand forecasts from changes made to our operational focus and ~~yield losses at~~current economic conditions, offset by lower sales to our ~~contract manufacturers, and a $0.2 million increase in other selling costs in the three months ended June 30, 2019.~~customers.

Gross profit was ~~$(4.6)~~$(19.6) million and ~~$(0.2)~~$(3.3) million for the three months ended ~~June 30,~~March 31, 2020 and 2019, ~~and 2018,~~ respectively. Gross profit as a percentage of revenue, or gross margin, was ~~(99)~~(545.4)% and ~~(6)~~(96.7)% for the three months ended ~~June 30,~~March 31, 2020 and 2019, ~~and 2018,~~ respectively. The decrease in gross profit was primarily due to ~~warranty expense and~~lower sales, inventory impairment charges ~~associated with product design changes~~ and ~~yield losses at~~reductions for one-time COVID-19 relief concessions and allowances offered to some of our ~~contract manufacturers.~~

~~Sales and marketing expenses~~

Sales and marketing expenses were $14.2 million for the three months ended June 30, 2019, compared to $6.2 million for the three months ended June 30, 2018, an increase of $8.0 million. The increase was primarily due to a $4.3 million increase in salaries, bonuses and payroll related costs for additional headcount, an increase in market research, consultants, and marketing costs of $2.2 million in connection with the U.S. launch of Eversense, and an increase of $1.5 million in other sales and general marketing expenses to support our European distribution of Eversense as well as in connection with our U.S. launch of Eversense.

~~Research and development expenses~~

Research and development expenses were $10.5 million for the three months ended June 30, 2019, compared to $8.3 million for the three months ended June 30, 2018, an increase of $2.2 million. The increase was primarily due to a $2.4 million increase in expenses related to clinical studies, partially offset by a $0.2 million decrease in development efforts at our contract manufacturers related to development of future generations of Eversense.

~~General and administrative expenses~~

~~General and administrative expenses were $5.4 million for both the three months ended June 30, 2019, and June 30, 2018.~~

~~Total other income (expense), net~~

Total other income (expense), net, was $3.6 million for the three months ended June 30, 2019, compared to $(12.4) million for the three months ended June 30, 2018, an increase of $16.0 million. The increase was primarily due to a $15.1 million change in fair value of the derivative liabilitylarger customers in the ~~three months ended June 30, 2019, compared to the three months ended June 30, 2018, partially offset by an increase of $0.9 million in interest expense on our Oxford/SVB Term Loans and 2023 Notes.~~

~~Comparison of the six months ended June 30, 2019 and 2018~~

~~The following table sets forth our results of operations for the six months ended June 30, 2019 and 2018 (in thousands).~~United States.

Table of Contents

Six Months Ended

June 30,

Period-to-

2019

2018

Period Change

(in thousands)

Revenue, net

$
2,718

$
931

$
1,787

Revenue, net - related parties

5,312

5,638

(326)

Cost of sales

15,893

7,147

8,746

Gross profit

(7,863)

(578)

(7,285)

Expenses:

Sales and marketing expenses

27,013

9,618

17,395

Research and development expenses

17,612

16,402

1,210

General and administrative expenses

11,933

9,393

2,540

Operating loss

(64,421)

(35,991)

(28,430)

Other income (expense), net:

Interest income

1,037

425

612

Interest expense

(3,999)

(4,007)

8

Change in fair value of derivative liability

6,961

(15,013)

21,974

Other income (expense)

(17)

(183)

166

  Total other income (expense), net

3,982

(18,778)

22,760

Net loss

$
(60,439)

$
(54,769)

$
(5,670)

~~Revenue, net~~

Our net revenue increased to $8.0 million for the six months ended June 30, 2019, compared to $6.6 million for the six months ended June 30, 2018. This increase was primarily due to sales of Eversense in the United States in the six months ended June 30, 2019 following our U.S. launch in July 2018, partially offset by gross to net reductions to revenue for the Eversense Bridge Program.

~~Cost of sales~~

Our cost of sales increased to $15.9 million for the six months ended June 30, 2019, compared to $7.1 million for the six months ended June 30, 2018. The increase was primarily due to $3.0 million of U.S. sales, a $1.8 million increase in warranty expense and obligations as a result of the January 2019 amendment of the Roche distribution agreement, an increase of $2.2 million for impairment charges for obsolete inventory associated with product design changes and yield losses at our contract manufacturers, and an increase of $1.7 million for lab supplies, shipping and duties, and logistics costs.

Our gross profit was $(7.9) million and $(0.6) million for the six months ended June 30, 2019 and 2018, respectively. Gross profit as a percentage of revenue, or gross margin, was (98)% and (9)% in the six months ended June 30, 2019 and 2018.

Sales and marketing expenses

Sales and marketing expenses were ~~$27.0~~$11.1 million for the ~~six~~three months ended ~~June 30, 2019,~~March 31, 2020, compared to ~~$9.6~~$12.8 million for the ~~six~~three months ended ~~June 30, 2018, an increase~~March 31, 2019, a decrease of ~~$17.4~~$1.7 million. The ~~$17.4 million increase~~decrease was primarily due to ~~a $9.0~~$2.1 million ~~increase~~for consulting expenses incurred in ~~salaries, bonuses and payroll related costs for additional headcount, an increase in sales related costs~~the first quarter of ~~$2.8 million~~2019 in connection with ~~the U.S. launch and commercialization of Eversense, and an increase of $5.6 million in other sales and general marketing expenses to support our European distribution of Eversense as well as~~activities supporting the U.S. launch of Eversense, ~~including~~and $0.3 million for travel ~~marketing programs~~ and ~~materials, and trade shows.~~

~~Table of Contents~~associated field sales expenses, partially offset by a net $0.7 million increase in personnel related costs primarily related to severance expenses in connection with our reduction in workforce on March 26, 2020.

Research and development expenses

Research and development expenses were ~~$17.6~~$7.4 million for the ~~six~~three months ended ~~June 30, 2019,~~March 31, 2020, compared to ~~$16.4~~$7.1 million for the ~~six~~three months ended ~~June 30, 2018,~~March 31, 2019, an increase of ~~$1.2~~$0.3 million. The increase ~~of $1.2 million~~ was primarily ~~due to~~a result of $0.4 million for clinical trial costs, $0.4 million for personnel related costs, including severance expenses in connection with our reduction in workforce on March 26, 2020, offset by a $0.5 million ~~increase~~decline in ~~salaries, bonuses~~general research and ~~payroll related costs for additional headcount and a $2.9 million increase in expenses related to clinical studies, partially offset by a $2.1 million decrease in~~ development ~~efforts at our contract manufacturers related to development of future generations of Eversense.~~activities.

General and administrative expenses

General and administrative expenses were ~~$11.9~~$5.7 million for the ~~six~~three months ended ~~June 30, 2019,~~March 31, 2020, compared to ~~$9.4~~$6.5 million for three months ended March 31, 2019, a decrease of $0.8 million. The decrease was primarily due to $0.7 million for personnel related costs from higher severance expenses incurred in the first quarter of 2019 and lower stock-based compensation.

Total other income, net

Total other income, net, was $1.2 million for the ~~six~~three months ended ~~June 30, 2018,~~March 31, 2020, compared to $0.4 million for the three months ended March 31, 2019, an increase of ~~$2.5~~$0.8 million. The increase was primarily due to ~~a $0.9~~an $8.2 million increase in ~~salaries, bonuses and payroll related costs for additional headcount, and an increase of $1.6 million in other general and administrative costs to support our operations.~~

~~Total other income (expense), net~~

~~Total other income (expense), net, was $4.0 million for~~ the ~~six months ended June 30, 2019, compared to $(18.8) million for the six months ended June 30, 2018, an increase of $22.8 million. The increase was primarily due to a $22.0 million~~ change in fair value of ~~the~~our derivative ~~liability during the six months ended June 30, 2019 compared to the six months ended June 30, 2019,~~liabilities, partially offset by a $4.5 million loss on extinguishment of our Loan and Security Agreement with Solar, $2.3 million of additional interest expense due to the 2025 Notes entered into in July 2019, a decline in interest income of $0.4 million and an increase in other expense of ~~$2.2 million in interest expense on our Oxford/SVB Term Loans and 2023 Notes, and a $0.7 million increase in investment income.~~

$0.1 million.

Liquidity and Capital Resources

Sources of Liquidity

ToFrom our founding in 1996 until 2010, we devoted substantially all of our resources to researching various sensor technologies and platforms. Beginning in 2010, we narrowed our focus to developing and refining a commercially viable glucose monitoring system. However, to date, we have not generated ~~any~~ significant revenue from the sale of our products and our ability to generate revenue and achieve profitability largely depends on our ability to successfully expand the commercialization of Eversense, continue the development of our products and product ~~sales. We have incurred substantial losses~~upgrades, and ~~cumulative negative cash flows from operations since our inception~~to obtain necessary regulatory approvals for the sale of those products, including approval by the FDA for the extended Eversense XL CGM system in ~~October 1996.~~the United States. These activities will require significant uses of working capital through 2020 and beyond. We have never been profitable, and our net losses were ~~$60.4~~$42.6 million and ~~$54.8~~$29.4 million for the ~~six~~three months ended ~~June 30~~,March 31, 2020 and 2019, ~~and 2018,~~ respectively. As of ~~June 30, 2019, our~~March 31, 2020, we had an accumulated deficit ~~totaled $418.2~~of $515.9 million.

To date, we have funded our operations principally through the issuance of preferred stock, common stock and debt. As of ~~June 30, 2019,~~March 31, 2020, we had cash, ~~and~~ cash equivalents, and restricted cash of ~~$65.3~~$18.8 million. ~~Under~~

We are pursuing strategic alternatives and have been in discussions with new financing sources, including subsequent financings received during April 2020 described under Indebtedness below. We plan to continue to seek additional financing, which could include issuing additional equity (including through the ~~Amended~~Open Market Sales agreement

Table of Contents

with Jefferies) or either secured or unsecured indebtedness or a combination of both.

Common Stock

In November 2019, we entered into an Open Market Sale Agreement with Jefferies LLC which allows us to issue and ~~Restated~~sell up to $50 million in gross proceeds of our common stock. As of March 31, 2019, the company has received $0.1 million in net proceeds from the sale of 175,089 shares under this agreement.

Indebtedness

Term Loans

As described in our Overview and Business Updates, on March 22, 2020 we terminated our Loan and Security Agreement with ~~Oxford~~Solar and ~~SVB, we borrowed an aggregate~~repaid the $45.0 million principal ~~amount of $25.0 million.~~balance in full.

Convertible Notes

In ~~January 2018,~~July 2019, we issued ~~$50.0 million in aggregate principal amount of 2023 Notes, and in February 2018, we issued an additional $3.0~~$82.0 million in aggregate principal amount of the ~~2023~~2025 Notes.

~~On June 28,~~ In the first quarter of 2018, pursuant to an underwriting agreement with BTIG, LLC, we closed the June 2018 Offering of 38,076,561 shares of our common stock, including BTIG, LLC’s exercise in full of its option to purchase additional shares, at a price of $3.93 per share. We received aggregate net proceeds of $149.0 million from the June 2018 Offering.

~~In July 2019, we~~ closed a follow-on public offering of 26,136,363 shares of our common stock at a price of $1.10 per share, which included the exercise in full by the underwriter of its option to purchase up to 3,409,090 additional shares. We received aggregate gross proceeds of $28.7 million from the offering, ~~before deducing underwriting discounts and offering expenses~~.

~~On July 25, 2019,~~ we issued ~~$82.0~~$53.0 million in aggregate principal amount of ~~our~~senior convertible notes that will mature on February 1, 2023, or the 2023 Notes. For additional information on the 2025 Notes and the 2023 Notes, see Note 7—Notes Payable and Stock Purchase Warrants in the ~~Notes Offering.~~ ~~We used $37.9~~accompanying unaudited consolidated financial statements.

The following table summarizes our outstanding senior convertible note obligations at March 31, 2020:

Aggregate

Initial Conversion

Conversion Price

Convertible

Issuance

Principal

Maturity

Rate per Share

per Share of

Note

Date

Coupon

(in millions)

Date

of Common Stock

Common Stock

2023 Notes

January 2018

5.25%

15.7

February 1, 2023

294.1176

3.40

2025 Notes

July 2019

5.25%

82.0

January 15, 2025

757.5758

1.32

Total

97.7

PPP Loan

On April 22, 2020, we received $5.8 million ~~of the net proceeds~~in loan funding from the ~~Notes Offering~~PPP pursuant to ~~repurchase $37.0 million aggregate principal amount our outstanding 2023 Notes at a purchase price equal to~~the CARES Act and administered by the SBA. The unsecured loan, or the PPP Loan, is evidenced by the PPP Note dated April 21, 2020, or the PPP Note, in the principal amount ~~thereof, plus accrued~~of $5.8 million with Silicon Valley Bank, or the Bank.

Under the terms of the PPP Note and ~~unpaid~~the PPP Loan, interest ~~thereon.~~accrues on the outstanding principal at a rate of 1.0% per annum. The term of the PPP Note is two years, though it may be payable sooner in connection with an event of default under the PPP Note. To the extent the loan amount is not forgiven under the PPP, we are obligated to make equal monthly payments of principal and interest, beginning seven months from the date of the PPP Note, until the maturity date.

The CARES Act and the PPP provide a mechanism for forgiveness of up to the full amount borrowed. Under the PPP, we may apply for forgiveness for all or a part of our PPP Loan. The amount of loan proceeds eligible for forgiveness is based on a formula that takes into account a number of factors, including the amount of loan proceeds used by us during the specified period after the loan origination for certain purposes including payroll costs, interest on debt obligations incurred prior to February 15, 2020, rent payments on certain leases, and certain qualified utility payments, provided that at least 75% of the loan amount is used for eligible payroll costs; the employer maintaining or rehiring employees and maintaining salaries at certain levels; and other factors. Subject to the other requirements and limitations on loan forgiveness, only loan proceeds spent on payroll and other eligible costs during the covered specified period will qualify for forgiveness. As a result of our workforce reduction, the amount of forgiveness will correspondingly decrease, unless we are able to rehire impacted employees during the specified period.

Table of Contents

The PPP Note may be prepaid in part or in full, at any time, without penalty. The PPP Note provides for certain customary events of default, including (i) failing to make a payment when due under the PPP Note, (ii) failure to do anything required by the PPP Note or any other loan document, (iii) defaults of any other loan with the Bank, (iv) failure to disclose any material fact or make a materially false or misleading representation to the Bank or SBA, (v) default on any loan or agreement with another creditor, if the Bank believes the default may materially affect our ability to pay the PPP Note, (vi) failure to pay any taxes when due, (vii) becoming the subject of a proceeding under any bankruptcy or insolvency law, having a receiver or liquidator appointed for any part of our business or property, or making an assignment for the benefit of creditors, (viii) having any adverse change in financial condition or business operation that the Bank believes may materially affect our ability to pay the PPP Note, (ix) if we reorganize, merge, consolidate, or otherwise change ownership or business structure without the Bank’s prior written consent, or (x) becoming the subject of a civil or criminal action that the Bank believes may materially affect our ability to pay the PPP Note. Upon the occurrence of an event of default, the Bank has customary remedies and may, among other things, require immediate payment of all amounts owed under the PPP Note, collect all amounts owing from us, and file suit and obtain judgment against us.

Highbridge Loan Agreement

On ~~July 16, 2019,~~April 21, 2020, we entered into the ~~Solar~~Highbridge Loan ~~Agreement. Following our closing~~Agreement, with certain funds managed by Highbridge Capital Management, LLC, or Highbridge, as the lenders (together with the other lenders from time to time party thereto, or the Lenders) and Wilmington Savings Fund Society, SCB, as collateral agent.

Pursuant to the Highbridge Loan Agreement, we may borrow up to an aggregate of $20.0 million in aggregate principal through the issuance and sale of the ~~Notes Offering, we borrowed an~~First Lien Notes. We received the first tranche of borrowing in the aggregate principal amount of ~~$45.0~~$15.0 million on April 24, 2020. Under the terms of the Highbridge Loan Agreement, we may issue up to an additional $5.0 million in aggregate principal amount of First Lien Notes in a subsequent closing. In connection with the Highbridge Loan Agreement and receipt of the first tranche of borrowing, we issued 1,500,000 shares of our common stock to the Lenders as a commitment fee.

The First Lien Notes are secured, senior obligations that bear interest at the annual rate of 12% or, at our election, payment in kind at an annual rate of 13%, payable monthly in arrears. The First Lien Notes will mature on October 24, 2021, or the First Lien Maturity Date, unless earlier repurchased, redeemed or converted in accordance with their terms. The obligations under the ~~Solar~~First Lien Notes are secured by substantially all our assets.

We have the right to prepay the First Lien Notes at any time, subject to a prepayment premium, which in certain circumstances we may elect to pay in our common stock, equal to the aggregate amount of interest payments through maturity. However, if the date of payment in cash of such prepayment premium is on or before August 22, 2020, the prepayment premium will be reduced by 25%.

Subject to certain conditions, if we retain or reinvest proceeds of an asset sale pursuant to the asset sale prepayment provisions in the Highbridge Loan ~~Agreement.~~ Agreement, the Lenders shall be entitled to convert First Lien Notes and Holders (defined below) shall be entitled to convert Second Lien Notes in aggregate combined principal amount equal to 45% of such net proceeds retained or reinvested (together with any applicable prepayment premium) to our common stock at a price per share equal to 90% of the greater of (i) the daily volume weighted average of the price per share of our common stock, on the conversion date, or if the conversion date is not a trading date, the trading day immediately prior to the conversion date and (ii) $0.57 per share. This conversion option has a daily limit of $1.0 million in aggregate converted principal (inclusive of principal amount of Second Lien Notes that are voluntarily converted by the Holders).

From and after a strategic transaction announcement (as defined in the form of First Lien Note), we may elect to convert up to $9.4 million in aggregate principal of the First Lien Notes to our common stock at a price per share equal to 90% of the greater of (i) the daily volume weighted average of the price per share of the Common Stock, on the conversion date, or if the conversion date is not a trading date, the trading day immediately prior to the conversion date and (ii) $0.57 per share of our common stock. This conversion option has a daily limit of $0.3 million in aggregate converted principal. If we or the Lenders elect to convert any of the First Lien Notes, the amount converted will be equal to the principal and unpaid accrued interest plus the applicable prepayment premium.

Table of Contents

Exchange Agreement with Highbridge

On April 21, 2020 we entered into a Note Purchase and Exchange Agreement, or the Exchange Agreement, with certain funds managed by Highbridge providing for the exchange of $24.0 million aggregate principal amount of our outstanding 2025 Notes for (i) $15.7 million aggregate principal amount of newly issued Second Lien Secured Notes due January 2022, or the Second Lien Notes, and, together with the First Lien Notes, the Senior Notes, (ii) 11,026,086 shares of our common stock, (iii) warrants to purchase up to 4,500,000 shares of our common stock at an exercise price of $0.66 per share, and (iv) $0.3 million in accrued and unpaid interest on the 2025 Notes being exchanged. The Exchange closed on April 24, 2020. The Warrants may be exercised in cash or on a cashless basis at any time through the three year anniversary of the issuance date.

The Second Lien Notes are secured, senior obligations, junior only to the First Lien Notes. The Second Lien Notes bear interest in cash at the annual rate of 7.5% or, at our election, payment in kind at an annual rate of 8.25%, payable monthly in arrears. The Second Lien Notes mature on January 24, 2022 unless earlier repurchased, redeemed or converted in accordance with their terms. The obligations under the Second Lien Notes are secured by substantially all of our assets.

We ~~used $11.6~~have the right to prepay the Second Lien Notes at any time, subject to a prepayment premium, which in certain circumstances we may elect to pay in our common stock, equal to the aggregate amount of interest payments through maturity. However, if the date of payment in cash of such prepayment premium is on or before August 22, 2020, the prepayment premium will be reduced by 25%.

The holders of the Second Lien Notes, or the Second Lien Notes Holders, will have the right to convert up to $7.0 million aggregate principal of the Second Lien Notes (together with any applicable prepayment premium) to our common stock at a price per share equal to 90% of the greater of (i) the daily volume weighted average of the price per share of our common stock, on the conversion date, or if the conversion date is not a trading date, the trading day immediately prior to the conversion date and (ii) $0.57 per share. This conversion option has a daily limit of $1.0 million in aggregate converted principal (inclusive of principal amount of First Lien Notes that are voluntarily converted by the Lenders). Subject to certain conditions, if we retain or reinvest proceeds of an asset sale pursuant to the asset sale prepayment provisions in the Exchange Agreement, the Second Lien Notes Holders shall be entitled to convert additional Second Lien Notes and the Lenders shall be entitled to convert First Lien Notes in aggregate combined principal amount equal to 45% of such net proceeds retained or reinvested (together with any applicable prepayment premium). As of June 5, 2020, the Holders have converted $4.8 million of ~~the Solar Term Loan to and repay in full the Oxford/SVB Term Loans.~~principal for issuance of 10,502,291 shares of our common stock.

From and after a strategic transaction announcement, we may elect to convert up to $8.7 million in aggregate principal of the Second Lien Notes to our common stock at a price per share equal to 90% of the greater of (i) the daily volume weighted average of the price per share of our common stock, on the conversion date, or if the conversion date is not a trading date, the trading day immediately prior to the conversion date and (ii) $0.57 per share. This conversion option has a daily limit of $0.3 million in aggregate converted principal. If we or the Second Lien Notes Holders elect to convert any of the Second Lien Notes, the amount converted will be equal to the principal and unpaid accrued interest plus the applicable premium.

Table of Contents

We may not issue shares of our common stock, net of the 18,181,818 shares underlying the 2025 Notes exchanged in the Exchange, in excess of 19.99% of our common stock outstanding on April 21, 2020; this restriction is subject to removal upon approval by our stockholders. We intend to seek this approval at our 2020 Annual Meeting of Stockholders on June 30, 2020.

Funding Requirements and Outlook

Given our limited cash resources, and after inclusion of our subsequent financings, and considering the economic and market uncertainty resulting from the COVID-19 pandemic, management has substantial doubt regarding our ability to meet our obligations as they become due in the ordinary course of business for the next twelve months from the date of this Quarterly Report on Form 10-Q. Our ability to generate ~~revenue and achieve profitability depends~~enough cash to meet our streamlined working capital requirements is dependent on our completion of the development of Eversense and future product candidates and obtaining and maintaining the necessary regulatory approvals for the manufacture, marketing and sales of those products. These activities, including our planned significant research and development efforts, will require significant uses of working capital through 2019 and beyond.

~~We expect our existing cash and cash equivalents, including the proceeds from the July 2019 follow-on public offering, the Notes Offering and the Solar Term Loans will be sufficient~~ability to fund our operations through the end of 2020. We have based this estimate on assumptions that may prove to be incorrect, and we could use our capital resources sooner than we currently expect. Additionally, the process of clinical and regulatory development of medical devices is costly, and the timing of progress of these efforts is uncertain.

We anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses and administrative expenses will continue to increase and, as a result, we will needachieve additional capital ~~to fund our operations. Until such time, if ever, as we can generate substantial revenue, we expect to finance our cash needs through a combination of debt financings, equity offerings,~~sources and ~~revenue~~favorable outcomes from potential ~~research~~strategic alternatives currently being explored. New financings may not be available to us on commercially acceptable terms, or at all, and ~~development~~may be impacted by new and ~~other collaboration agreements.~~current debt covenants. To the extent that we raise additional capital through debt or the ~~future~~ sale of equity, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our existing common stockholders. If we raise additional funds ~~in the future,~~or enter into strategic development, distribution, or licensing arrangements, we may have to relinquish valuable rights to our technologies, future revenue streams or grant ~~licenses on~~ terms that may not be favorable to us. If we are unable to raise additional funds through equity, or debt financings, ~~when needed,~~or strategic alliances, we may be required to further delay, limit, reduce or terminate ~~our product development or future commercialization efforts or grant licenses to develop and market products that we would otherwise prefer to develop and market ourselves.~~

~~Indebtedness~~

~~Term Loans~~

On June 30, 2016, we entered into an Amended and Restated Loan and Security Agreement with Oxford and SVB. Pursuant to the Amended and Restated Loan and Security Agreement, we borrowed an aggregate principal amount of $25.0 million. We refer to these borrowings as the Oxford/SVB Term Loans. ~~As described below, in July 2019, we used $11.6 million~~ ~~of the Solar Term Loan to repay in full the Oxford/SVB Term Loans and terminate our~~ ~~Amended and Restated Loan and Security Agreement~~ ~~with Oxford and SVB.~~

The Oxford/SVB Term Loans bore interest at a floating annual rate of 6.31% plus the greater of (i) 90-day U.S. Dollar LIBOR reported in the Wall Street Journal or (ii) 0.64%, provided that the minimum floor interest rate is 6.95%, and require monthly payments. The monthly payments initially consisted of interest-only through December 31, 2017. In January 2018, we began to make monthly principal payments.

~~We elected to prepay all Oxford/SVB Term Loans prior to the Maturity Date subject to a prepayment fee equal to 1.00%. As of~~ ~~June 30, 2019, the outstanding balance of the Oxford/SVB Term Loans was $10.0 million.~~

Pursuant to the Amended and Restated Loan and Security Agreement, we also issued to Oxford and SVB10-year stock purchase warrants to purchase an aggregate of 116,581, 63,025 and 80,645 shares of common stock with exercise prices of $3.86, $2.38, and $1.86 per share, respectively.

We incurred issuance costs related to the Oxford/SVB Term Loans of approximately $0.6 million that are being amortized as additional interest expense over the term of the Oxford/SVB Term Loans using the effective interest method. The fair value of the stock purchase warrants, which was estimated to be $0.5 million, was recorded as a

~~Table of Contents~~

~~discount to the Oxford/SVB Term Loans, which is also being amortized as additional interest expense over the term of the Oxford/SVB Term Loans using the effective interest method.~~

We were also required to make a final payment equal to 9.00% of the aggregate principal balances of the funded Oxford/SVB Term Loans. This fee is being accrued as additional interest expense over the term of the Oxford/SVB Term Loans using the effective interest method.

On July 16, 2019, we entered into the Solar Loan Agreement with the Lenders. Pursuant to the Solar Loan Agreement, on July 25, 2019, we borrowed the Solar Term Loan in an aggregate principal amount of $45.0 million. ~~We used $11.6 million~~ ~~of the Solar Term Loan to repay in full the Oxford/SVB Term Loans and terminate our~~ ~~Amended and Restated Loan and Security Agreement~~ ~~with Oxford and SVB.~~

Interest on the Solar Term Loan will be payable monthly at a floating annual rate of 6.50% plus the greater of (i) the rate per annum rate published by the Intercontinental Exchange Benchmark Administration Ltd. and (ii) 2.48%, provided that the minimum floor interest rate is 8.98%. The maturity date for the Solar Term Loan will be June 1, 2024, or the Solar Maturity Date. Commencing on August 1, 2021, we will be required to make monthly principal amortization payments; provided that the interest only period may be extended to (i) August 1, 2022 if our product revenue is greater than or equal to $40.0 million on a trailing six-month basis prior to the second anniversary of the effective date and (ii) August 1, 2023 if our product revenue is greater than or equal to $75.0 million on a trailing six-month basis after the achievement of the first extension.

We may elect to prepay the Solar Term Loan prior to the Solar Maturity Date subject to a prepayment fee equal to 3.00% if the prepayment occurs within one year of the effective date, 2.00% if the prepayment occurs during the second year following the effective date, and 1.00% if the prepayment occurs more than two years after the effective date and prior to the Solar Maturity Date.

The Solar Loan Agreement contains customary events of default, including bankruptcy, the failure to make payments when due, the occurrence of a material impairment on the Lenders’ security interest over the collateral, a material adverse change, the occurrence of a default under certain other agreements entered into by us, the rendering of certain types of judgments against us, the revocation of certain government approvals, violation of covenants, and incorrectness of representations and warranties in any material respect. Upon the occurrence of an event of default, subject to specified cure periods, all amounts owed by us would begin to bear interest at a rate that is 5.00% above the rate effective immediately before the event of default, and may be declared immediately due and payable by the Lenders.

~~The Solar Term Loan is secured by substantially all~~some of our ~~assets. The Solar Loan Agreement also contains specified financial covenants related to our liquidity and trailing six-month revenues.~~operating plans.

The Solar Loan Agreement also contains certain restrictive covenants that limit our ability to incur additional indebtedness and liens, merge with other companies or consummate certain changes of control, acquire other companies, engage in new lines of business, make certain investments, pay dividends, transfer or dispose of assets, amend certain material agreements or enter into various specified transactions, as well as financial reporting requirements.

~~Convertible Notes~~

In January 2018, we issued $50.0 million in aggregate principal amount of 2023 Notes, and in February 2018, we issued an additional $3.0 million in aggregate principal amount of 2023 Notes. The 2023 Notes are general, unsecured, senior subordinated obligations and bear interest at a rate of 5.25% per year, payable semiannually in arrears on February 1 and August 1 of each year, beginning on August 1, 2018. The 2023 Notes will mature on February 1, 2023, unless earlier repurchased or converted. Payment of the principal of, and accrued and unpaid interest, if any, on the maturity date, and the fundamental change repurchase price of (excluding cash payable in lieu of delivering fractional shares of our common stock), the 2023 Notes is subordinated to the prior payment in full in cash or other payment satisfactory to the holders of senior debt, of all existing and future senior debt, which includes our indebtedness under the Amended and Restated Loan and Security Agreement with Oxford and SVB and any refinancing thereof.

~~Table of Contents~~

The 2023 Notes are convertible into shares of our common stock at the option of the holders at any time prior to the close of business on the business day immediately preceding the maturity date. The conversion rate is initially 294.1176 shares of common stock per $1,000 principal amount of 2023 Notes (equivalent to an initial conversion price of approximately $3.40 per share of common stock), subject to customary adjustments. Holders who convert on or after the date that is six months after the last date of original issuance of the 2023 Notes but prior to February 1, 2021, may also be entitled to receive, under certain circumstances, an interest make-whole payment payable in shares of our common stock. In addition, following certain corporate events that occur prior to the maturity date, we will, in certain circumstances, increase the conversion rate for a holder who elects to convert its 2023 Notes in connection with such a corporate event.

~~In the second quarter of 2018, we issued 73,529 shares of common stock upon the conversion of $250,000 in aggregate principal amount of the 2023 Notes.~~ ~~There was no conversion of 2023 Notes in the second quarter of 2019.~~

~~As of~~ ~~June 30, 2019, the aggregate outstanding principal amount of the 2023 Notes was $52.7 million.~~

In July 2019, we issued $82.0 million in aggregate principal amount of 2025 Notes. The 2025 Notes are general, unsecured, senior subordinated obligations and bear interest at a rate of 5.25% per year, payable semiannually in arrears on January 15 and July 15 of each year, beginning on January 15, 2020. The 2025 Notes will mature on January 15, 2025, unless earlier repurchased or converted.

We used $37.9 million of the net proceeds from the issuance of the 2025 Notes to repurchase $37.0 million aggregate principal amount of outstanding 2023 Notes, at a purchase price equal to the principal amount thereof, plus accrued and unpaid interest thereon.

The 2025 Notes are convertible, at the option of the holders, into shares of our common stock, at an initial conversion rate of 757.5758 shares per $1,000 principal amount of the 2025 Notes (equivalent to an initial conversion price of approximately $1.32 per share).

We may redeem for cash all or part of the 2025 Notes, at our option, if (1) the last reported sale price of our common stock has been at least 150% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide notice of redemption and (2) a registration statement covering the resale of the shares of our common stock issuable upon conversion of the 2025 Notes is effective and available for use and is expected to remain effective and available for use during the redemption period as of the date of the redemption notice date. The redemption price will be equal to 100% of the principal amount of the 2025 Notes to be redeemed plus accrued and unpaid interest to, but excluding, the redemption date.

If we undergo a fundamental change, holders may require us to repurchase for cash all or any portion of their 2025 Notes at a fundamental change repurchase price equal to 100% of the principal amount of the 2025 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. In addition, following a notice of redemption or certain corporate events that occur prior to the maturity date, we will, in certain circumstances, increase the conversion rate for a holder who elects to convert its 2025 Notes in connection with such notice of redemption or corporate event. In certain circumstances, we will be required to pay cash in lieu of delivering make whole shares unless we obtain stockholder approval to issue shares.

~~Table of Contents~~

Cash Flows

The following is a summary of cash flows for each of the periods set forth below (in thousands).

Six Months Ended

June 30,

2019

2018

(unaudited)
Net cash used in operating activities

$
(65,855)

$
(40,367)

Net cash (used in) provided by investing activities

(736)

12,239

Net cash (used in) provided by financing activities

(4,906)

195,906

Net (decrease) increase in cash and cash equivalents

$
(71,497)

$
167,778


	Three Months Ended
	March 31,
	2020		2019
Net cash used in operating activities	$	(29,048)	$	(30,152)
Net cash used in investing activities		(100)		(490)
Net cash used in financing activities		(47,985)		(2,476)
Net decrease in cash, cash equivalents and restricted cash	$	(77,133)	$	(33,118)

Net cash used in operating activities

Net cash used in operating activities was ~~$65.9~~$29.0 million for the ~~six~~three months ended ~~June 30, 2019,~~March 31, 2020 and consisted of a net loss of ~~$60.4~~$42.6 million, a net change in operating assets and liabilities of $4.1 million mostly due to collections of accounts receivable at December 31, 2019 collected from Roche in the first quarter of 2020 and reductions in inventory, net for increased impairment reserves, as well as net non-cash items of $10.0 million, including a change of $12.5 million for inventory net realizable value charges, and a $4.5 million extinguishment loss on the Solar Loan Agreement, offset by a $8.2 million change in fair value of the embedded derivatives on the 2023 and 2025 Notes over the prior period.

Net cash used in operating activities was $30.2 million for the three months ended March 31, 2019 and

Table of Contents

consisted of a net loss of $29.4 million and a net change in operating assets and liabilities of ~~$7.3~~$1.9 million, partially offset by net non-cash items of ~~$1.9~~$1.1 million. Net change in operating assets and liabilities consisted of ~~an $8.9~~a $4.2 million increase in inventory, a ~~$0.4~~$1.1 million ~~increase~~decrease in accounts payable, a ~~$2.1~~$0.7 million increase in prepaid expenses and other current assets ~~$0.2 million of lease payments,~~ and a $0.6 million decrease in deferred revenue, partially offset by a ~~$1.3~~$4.7 million decrease in accounts ~~receivable, $0.2 million of accrued interest on Term Loans, and a $2.6 million increase in accrued expenses and other current liabilities.~~receivable. Net non-cash items consisted of stock-based compensation expense of ~~$4.3~~$2.0 million, non-cash interest expense of ~~$1.9~~$0.9 million, depreciation and amortization of ~~$0.4 million, and an increase in the provision for inventory obsolescence of $2.3~~$0.2 million, partially offset by decrease in fair value of derivative liability of ~~$7.0~~$2.1 million.

Net cash used in operating activities was $40.4 million for the six months ended June 30, 2018, and consisted of a net loss of $54.8 million and a net change in operating assets and liabilities of $5.4 million (consisting of a net increase in accounts receivable, prepaid expenses and other current assets, inventory, and deposits and other assets of $7.4 million, net of an increase in accounts payable, accrued expenses and other current liabilities, accrued interest, and deferred rent of $2.0 million), partially offset by stock-based compensation expense of $3.1 million, an increase in the fair value of derivative liability of $15.0 million, non-cash interest expense of $1.5 million, and depreciation and write-down of the carrying value of our inventory to net realizable value of an aggregate amount of $0.2 million.

~~Net cash (used in) provided by~~ investing activities

Net cash used in investing activities was ~~$0.7~~$0.1 million for the ~~six~~three months ended ~~June 30,~~March 31, 2020 and consisted of capital expenditures for laboratory equipment.

Net cash used in investing activities was $0.5 million for the three months ended March 31, 2019 and consisted of ~~$0.7~~$0.4 million of capital expenditures for laboratory equipment and ~~production equipment at our contract manufacturers.~~$0.1 million of lease payments.

Net cash provided by investing activities was $12.2 million for the six months ended June 30, 2018, and consisted sales and maturities of marketable securities of $20.3 million, offset by purchases of marketable securities of $7.9 million and capital expenditures of $0.2 million.

~~Net cash (used in) provided by~~used in financing activities

Net cash used in financing activities was ~~$4.9~~$48.0 million for the ~~six~~three months ended ~~June 30,~~March 31, 2020 and primarily consisted of $45.0 for the repayment of outstanding principal on our Solar Loan Agreement and $3.4 million for a final payoff fee and prepayment premium.

Net cash used in financing activities was $2.5 million for the three months ended March 31, 2019 and consisted of aggregate principal payments on ~~our Oxford/SVB Term Loans~~term loans of ~~$5.0 million, partially offset by proceeds from the exercise of stock options of $0.1~~$2.5 million.

~~Net cash provided by financing activities was $195.9~~Contractual Obligations

The following summarizes our contractual obligations as of March 31, 2020:


	Payment due by period
			Remainder of						After
Contractual Obligations	Total		2020		2021-2022		2023-2024		2024
Operating lease obligations	$	3,279	$	708	$	1,971	$	600	$	-
Principal payment under 2023 Notes		15,700		-		-		15,700		-
Interest payments under 2023 Notes		2,473		412		1,649		412		-
Principal payment under 2025 Notes⁽¹⁾		82,000		-		-		-		82,000
Interest payments under 2025 Notes⁽¹⁾		22,031		2,180		8,759		8,759		2,333
Other commitments⁽²⁾		1,500		1,500		-		-		-
Total contractual obligations	$	126,983	$	4,800	$	12,379	$	25,471	$	84,333

(1)

Pursuant to the Exchange Agreement on April 21, 2020, $24.0 million aggregate principal amount of 2025 Notes were exchanged for (i) $15.7 million aggregate principal amount of Second Lien Notes (ii) 11,026,086 shares of our common stock, (iii) warrants to purchase up to 4,500,000 shares of our common stock at an exercise price of $0.66 per share, and (iv) $0.3 million in accrued and unpaid interest on the 2025 Notes being exchanged. The contractual obligations for the 2025 Notes do not reflect this subsequent event.

(2)

Other commitments include, among other things, minimum payment obligations and other obligations that we cannot cancel or where we would be required to pay a fee for termination before the contractual period ended. These do not include obligations negotiated with suppliers and contract manufacturers subsequent to the quarter ended March 31, 2020.

Off-Balance Sheet Arrangements

Except as described below, during the ~~six~~three months ended ~~June 30, 2018,~~March 31, 2020, we did not have any other, and consisted primarily of $149.4 million from the issuance of common stock in our June 2018 Offering, $50.7 million from the issuance of the 2023 Notes, and $1.0 million from the exercise of stock options, partially offsetwe currently do not have any other, off-balance sheet arrangements as defined by ~~aggregate principal payments on our Oxford/SVB Term Loans of $5.0 million.~~SEC rules.

Table of Contents

~~Contractual~~Subsequent Supplier and Contract Manufacturer Obligations

As of ~~June 30~~, 2019, there was no material change in our contractual obligations and commitments from those disclosed in our Annual Report on Form 10-K for the year ended December 31, 2018 filed with the SEC on March 15, 2019.

~~We issued the 2025 Notes subsequent to June 30, 2019. The $82.0 million principal amount~~a result of the ~~2025 Notes is payable in full at maturity on~~ ~~January 15, 2025. The interest payment schedule for the 2025 Notes is as follows: $0.0 million, $8.5 million, $8.6 million and $6.5 million for 2019, 2020-2021, 2022-2023 and after 2023, respectively.~~

~~As described elsewhere in this report, we repurchased $37.0 aggregate principal amount~~impact of the 2023 Notes with a portion of the proceeds from the offering of the 2025 Notes subsequent to June 30, 2019. The remaining $15.2 million principal amount of the 2023 Notes is payable in full at maturity on ~~February 1, 2023. The interest payment schedule for the 2023 Notes is as follows: $0.5 million, $1.7 million and $0.9 million for the remainder of 2019, 2020-2021 and 2022-2023, respectively.~~

We also borrowed the Solar Term Loan subsequent to June 30, 2019. The principal payment schedule for the Solar Term Loan is as follows: $0.0 million, $6.4 million, $30.8 million and $7.7 million for 2019, 2020-2021, 2022-2023 and after 2023, respectively. The interest payment schedule for the Solar Term Loan, basedCOVID-19 pandemic on the ~~prevailing rate on such borrowings as of the date of the filing of this report, is as follows: $1.4 million, $8.1 million, $4.3 million~~global healthcare community and ~~$0.2 million for 2019, 2020-2021, 2022-2023 and after 2023, respectively.~~

~~As described elsewhere in this report, we repaid all amounts outstanding under~~ our ~~Amended and Restated Loan and Security Agreement with Oxford and SVB with a portion of the procees from the Solar Term Loan.~~

~~Off‑Balance Sheet Arrangements~~

~~During three and six months ended June 30, 2019 we did not have, and we do not currently have, any off‑balance sheet arrangements, as defined under SEC rules.~~

~~JOBS Act~~

In April 2012, the JOBS Act was enacted. Section 107(b) of the JOBS Act provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this extended transition period, and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.

Atstreamlined operational focus implemented at the end of the ~~2019 fiscal year,~~first quarter of 2020, we ~~will no longer be an emerging growth company~~have been negotiating with certain of our major suppliers and ~~we will no longer be exempt from (i) providing an auditor’s attestation report~~contract manufacturers to pay for materials procured by these parties on our ~~system~~behalf or for costs incurred related to Eversense manufacturing activities that we paused or delayed. Some of ~~internal controls over~~these fees may also be dependent on whether the materials will expire prior to when we resume production at normal operating levels, or if further delays in manufacturing occur. As of June 9, 2020, we expect to have to pay approximately $1.9 million for costs related to pausing manufacturing activities and $0.6 million if certain manufacturing timelines are not met within a specified period. We will record any fees contingent upon future manufacturing timing in its consolidated financial ~~reporting pursuant to Section 404(b)~~statements if, and when, it is probable such obligations will become due. When we resume manufacturing activities, some of the ~~Sarbanes-Oxley Act and (ii) complying with any requirement that~~amounts paid for materials may be ~~adopted by the PCAOB regarding mandatory audit firm rotation or regarding a supplement~~credited back to ~~the auditor’s report providing additional information about the audit and the financial statements, known as the auditor discussion and analysis.~~

~~Critical Accounting Policies and Significant Judgments and Estimates~~

Our management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP. The preparation of these financial statements requires us to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities as of the dates of the balance sheets and the reported amounts of revenue and expenses during the reporting periods. In accordance with U.S. GAAP, we base our estimates on historical experience and on various other assumptions that we believe are reasonable under the circumstances at the time such estimates are made. Actual resultsupon consumption.

~~Table of Contents~~

may differ materially from our estimates and judgments under different assumptions or conditions. We periodically review our estimates in light of changes in circumstances, facts and experience. The effects of material revisions in estimates are reflected in our financial statements prospectively from the date of the change in estimate.

Management considers an accounting policy to be critical if it is important to our financial condition and results of operations, and if it requires significant judgment and estimates on the part of management in its application. The development and selection of these critical accounting policies have been determined by our management. Due to the significant judgment involved in selecting certain of the assumptions used in these areas, it is possible that different parties could choose different assumptions and reach different conclusions.

We believe there have been no material changes to our critical accounting policies and use of estimates as disclosed in the footnotes to our audited financial statements for the year ended December 31, 2018 included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 15, 2019.

ITEM 3: Quantitative and Qualitative Disclosures about Market Risk

Interest Rate Risk

The market risk inherent in our financial instruments and in our financial position represents the potential loss arising from adverse changes in interest rates. As of ~~June 30, 2019,~~March 31, 2020, we had cash, ~~and~~ cash equivalents, and restricted cash of ~~$65.3~~$18.8 million. We generally hold our cash in interest-bearing money market ~~accounts.~~accounts or short-term investments that meet our policy for cash equivalents. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. ~~Additionally, the interest rates on our 2025 Notes and 2023 Notes are fixed. The rate on borrowings under our Solar Term Loan is variable, subject to a minimum floor interest rate.~~ Due to the short-term maturities of our cash equivalents and the ~~minimum interest rate on the Solar Term Loan,~~low risk profile of our investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our ~~results of operations.~~cash equivalents. The interest rates on our 2023 and 2035 Notes are fixed, as are the interest rates on the First Lien Notes and Second Lien Notes. We do not currently engage in hedging transactions to manage our exposure to interest rate risk.

Foreign Currency Risk

The majority of our international sales are denominated in Euros. Therefore, our U.S. dollar value of sales is impacted by exchange rates versus the ~~dollar.~~Euro. Currency fluctuations or a strengthening U.S. dollar can decrease our revenue from these Euro-denominated international sales. To date, foreign currency transaction gains and losses and exchange rate fluctuations have not been material to our consolidated financial statements, and we do not believe that the effect of a hypothetical 10% change in foreign currency exchange rates applicable to our business would have had a material impact on our operating results or financial condition. We do not currently engage in any hedging transactions to manage our exposure to foreign currency exchange rate risk.

In addition, the uncertainty that exists with respect to the economic impact of the global COVID-19 pandemic has introduced significant volatility in the financial markets subsequent to our quarter ended March 31, 2020, which could increase our foreign currency and interest rate risk.

Table of Contents

ITEM 4: Controls and Procedures

Changes to Smaller Reporting Company Requirements

On March 12, 2020, the SEC voted to adopt amendments to the “accelerated filer” and “large accelerated filer” definitions in Rule 12b-2 under the Securities Exchange Act of 1934, or the Exchange Act. The amendments more appropriately tailor the types of issuers that are included in the categories of accelerated and large accelerated filers and promote capital formation, preserve capital, and reduce unnecessary burdens and compliance costs for certain smaller issuers while maintaining investor protections. As a result, certain low-revenue issuers will not be required to have their management’s assessment of the effectiveness of internal control over financial reporting, or ICFR, attested to, and reported on, by an independent auditor, as required by Section 404(b) of the Sarbanes-Oxley Act, or SOX. However, those issuers will remain obligated, among other things, to establish and maintain ICFR and, as required by SOX Section 404(a), have management assess the effectiveness of ICFR. Additionally, the amendments revise certain transition thresholds for accelerated and large accelerated filers and add an ICFR auditor attestation check box to the cover page of Form 10-K.

The 2019 fiscal year was the first year we were required to have an auditor’s attestation report on our system of ICFR pursuant to SOX. As a result of these amendments, we are no longer required to have our independent auditor attest to our ICFR. We expect material savings in our audit fees for 2020 as a result of this change, which become effective on April 27, 2020 and apply to our annual report on Form 10-K for the year ended December 31, 2020.

Evaluation of Disclosure Controls and Procedures

~~Under the supervision of and~~Our management, with the ~~participation~~assistance of ~~our management, including~~ our chief executive officer, who is our principal executive officer, and our chief financial officer, who is our principal financial officer, ~~we conducted an evaluation of~~has reviewed and evaluated the effectiveness of our disclosure controls and procedures ~~as of June 30, 2019, the end of the period covered by this Quarterly Report. The term “disclosure controls and procedures,” as set forth~~(as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as ~~amended, or the Exchange Act, means controls and other procedures~~amended) as of a company that are designed to provide reasonable assurance that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the rules and forms promulgated by the SEC. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the

~~Table of Contents~~

~~company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.~~

~~In designing and evaluating our disclosure controls and procedures, management~~March 31, 2020. Management recognizes that ~~disclosure~~any controls and procedures, no matter how well ~~conceived~~designed and operated, can provide only reasonable ~~not absolute,~~ assurance ~~that the~~of achieving their objectives ~~of the disclosure controls~~ and ~~procedures are met. Additionally, in designing disclosure controls and procedures, our~~ management necessarily ~~was required to apply~~applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and ~~procedures. The design~~procedures are designed to provide reasonable assurance of ~~any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in~~ achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in asuch control ~~system, misstatements due to error or fraud may occur and not be detected.~~objectives. Based on the evaluation of our disclosure controls and procedures as of ~~June 30, 2019,~~March 31, 2020, our chief executive officer and chief financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control over Financial Reporting

There ~~was~~were no ~~change~~changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the quarter ended ~~June 30, 2019~~March 31, 2020 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II: OTHER INFORMATION

ITEM 1: Legal Proceedings

From time to time, we are subject to litigation and claims arising in the ordinary course of business. We are not currently a party to any material legal proceedings, and we are not aware of any pending or threatened legal proceeding against us that we believe could have a material adverse effect on our business, operating results or financial ~~condition~~.condition.

ITEM 1A: Risk Factors

Our business is subject to risks and events that, if they occur, could adversely affect our financial condition and results of operations and the trading price of our securities. Except as described below, our risk factors as of the date of this Quarterly Report on Form 10-Q have not changed materially from those described in “Part I, Item 1A. Risk Factors”

Table of Contents

of our Annual Report on Form 10-K for the fiscal year ended December 31, ~~2018,~~2019, filed with the SEC on March ~~15, 2019.~~16, 2020, as amended on April 28, 2020.

~~Risks Related~~We are exploring strategic alternatives and there can be no assurance that we will be successful in identifying, undertaking or completing any strategic alternative, that any such strategic alternative will address our capital and business needs or that the process will not have an adverse impact on our business.

In March 2020, we announced that our Board of Directors has decided to ~~Our Indebtedness~~explore potential strategic alternatives to enhance stakeholder value. The process of reviewing and pursuing strategic alternatives may be time consuming and disruptive to our business operations and, if we are unable to effectively manage the process, our business, financial condition and results of operations could be adversely affected. We could incur substantial expenses associated with identifying and evaluating potential strategic alternatives. No decision has been made with respect to any strategic alternative and we cannot assure you that we will be able to identify, undertake and complete any strategic alternative that will address our capital and operational needs.

~~If holders~~Any potential strategic alternative would be dependent upon a number of ~~2023 Notes object~~factors that may be beyond our control. We do not intend to comment regarding the ~~amendment~~evaluation of ~~the 2023 Notes indenture, it could~~strategic alternatives until such time as we have determined that further disclosure is necessary or appropriate. As a ~~material~~consequence, perceived uncertainties related to our future may have an adverse ~~effect~~impact on our business, operations, and the market price of our common stock.

Our business, product sales and results of operations could be adversely affected by the effects of health epidemics, including the recent COVID-19 outbreak, in regions where we or third parties distribute our products or where we or third parties on which we rely have significant manufacturing facilities, concentrations, clinical trial sites or other business operations. The COVID-19 pandemic could materially affect our operations, including at our headquarters in Maryland and at our clinical trial sites, as well as the business or operations of our manufacturers, distributors or other third parties with whom we conduct business.

Our business could be adversely affected by health epidemics in regions where we have concentrations of clinical trial sites or other business operations, and could cause significant disruption in the operations of third-party manufacturers and distributors upon whom we rely.

For example, in December 2019, a novel strain of coronavirus, SARS-CoV-2, causing a disease referred to as COVID-19, was reported to have surfaced in Wuhan, China. Since then, COVID-19 has spread to multiple countries, including the United States and several European countries. Our headquarters is located in Maryland, and our contract manufacturers are located in Germany, the United Kingdom and the United States. Our distributors are located in the United States and various countries in Europe.

In March 2020, the World Health Organization declared the COVID-19 outbreak a pandemic, and the U.S. government imposed travel restrictions on travel between the United States, Europe and certain other countries. Further, the President of the United States declared the COVID-19 pandemic a national emergency, invoking powers under the Stafford Act, the legislation that directs federal emergency disaster response. Similarly, the Governor of Maryland has issued an order closing all non-essential businesses, which took effect on March 23, 2020. Substantially all of our workforce is now working from home either all or substantially all of the time. The effects of the Maryland order and our work-from-home policies may negatively impact productivity, disrupt our business and delay our clinical programs, regulatory and commercialization timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. These and similar, and perhaps more severe, disruptions in our operations could negatively impact our business, operating results and financial condition.

~~In connection with~~Quarantines, shelter-in-place and similar government orders, or the ~~Notes Offering,~~ ~~we launched a consent solicitation to holders~~perception that such orders, shutdowns or other restrictions on the conduct of ~~the 2023 Notes seeking consent to amend the indenture~~business operations could occur, related to COVID-19 or other infectious diseases could impact personnel at third-party manufacturing facilities in the ~~2023 Notes to remove a restrictive covenant that limited~~United States and other countries, or the availability or cost of materials, which would disrupt our ~~ability to incur additional indebtedness. On July 25, 2019, we received~~supply chain. In particular, some of our suppliers of certain materials used in the ~~requisite consents from holders~~production of our sensors and transmitters are located in Germany, the ~~2023 Notes to amend the indenture related to the 2023 Notes and entered into a Second Supplemental Indenture to reflect the foregoing amendment~~. The holders that consented to the amendment of the indenture related to the 2023 Notes may have interests that may differ from other holders of the 2023 Notes, including the fact that certain of such holders purchased a portion of the 2025 Notes and we repurchased their 2023 Notes with a portion of the net proceeds of the Notes Offering. If the remaining holders of the 2023 Notes object to the entry into the Second Supplemental Indenture, they could challenge the issuance of the 2025 NotesUnited Kingdom, China, Japan and the borrowing of the Solar Term Loan. Any such challenge could divert management's attention from our day-to-day operations and could have a material adverse effect on our business and financial condition.

Table of Contents

United States. For example, any manufacturing supply interruption of Eversense or future generation products, could adversely affect our ability to conduct planned clinical trials and commercialization activities.

Sales and demand for Eversense may be adversely affected by the global COVID-19 pandemic. Disruptions in the distributions of Eversense could result if patients are physically quarantined, if physicians restrict access to their facilities for a material period of time, if patients are unable or unwilling to visit health care providers, or if health care providers prioritize treatment of acute or communicable illnesses over diabetes management. We have begun to receive indications that insertions of Eversense have slowed during the pandemic, and this slowing could continue or worsen.

In addition, our clinical trials may be affected by the COVID-19 pandemic. Clinical site initiation and patient enrollment may be delayed due to prioritization of hospital resources toward the COVID-19 pandemic. Some patients may not be able to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. Similarly, our ability to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19 and adversely impact our clinical trial operations.

The spread of COVID-19, which has caused a broad impact globally, may materially affect us economically. While the potential economic impact brought by, and the duration of, COVID-19 may be difficult to assess or predict, a widespread pandemic could result in significant disruption of global financial markets, reducing our ability to access capital, which could negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock.

The global pandemic of COVID-19 continues to rapidly evolve. The ultimate impact of the COVID-19 pandemic or a similar health epidemic is highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, commercialization efforts, healthcare systems or the global economy as a whole. However, these effects could have a material impact on our operations, and we will continue to monitor the COVID-19 situation closely.

Restrictive covenants under the indentures related to the 2023 Notes and the 2025 Notes, the Highbridge Loan Agreement and the ~~Solar Loan~~Exchange Agreement may limit the manner in which we operate.

The indentures related to the 2023 Notes and the 2025 Notes, the Exchange Agreement, and the ~~Solar~~Highbridge Loan Agreement contain, and any future indebtedness we incur may contain, various negative covenants that restrict, among other things, our ability to:

incur additional indebtedness, guarantee indebtedness or issue disqualified stock or, in the case of such subsidiaries, preferred stock;

declare or pay dividends on, repurchase or make distributions in respect of, their capital stock or make other restricted payments;

make investments or acquisitions;

create liens;

enter into agreements restricting certain subsidiaries' ability to pay dividends or make other intercompany transfers;

consolidate, merge, sell or otherwise dispose of all or substantially all of our assets and the assets of our restricted subsidiaries;

enter into transactions with affiliates;

sell, transfer or otherwise convey certain assets; and

prepay certain types of indebtedness.

In addition, the ~~Solar~~Highbridge Loan Agreement ~~has~~and the Exchange Agreement have minimum liquidity ~~and monthly net product revenue~~ requirements and the ~~Solar Term~~Highbridge Loan ~~and other~~Agreement includes a covenant requiring the Company to operate within an approved budget. Our obligations under both the ~~Solar~~Highbridge Loan Agreement and the Exchange Agreement are be secured by substantially all of our assets. As a result, we are limited in the manner in which we conduct our business and we may be unable to engage in favorable business activities, repurchase shares of our common stock or finance future operations or capital needs.

Table of Contents

Servicing our debt requires a significant amount of cash, and we may not have sufficient cash flow from our business to pay our substantial debt.

Our ability to make scheduled payments of the principal of, to pay interest on or to refinance our indebtedness depends on our future performance, which is subject to economic, financial, competitive and other factors beyond our ~~control.~~control, including uncertainties related to the COVID-19 pandemic. Our business may not generate cash flow from operations in the future sufficient to service our debt and make necessary capital expenditures. If we are unable to generate such cash flow, we may be required to adopt one or more alternatives, such as selling assets, restructuring debt or obtaining additional equity capital on terms that may be onerous or highly dilutive. Our ability to refinance our indebtedness will depend on the capital markets and our financial condition at such time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our debt obligations.

Despite our current debt levels, subject to certain conditions and limitations, we may still incur substantially more debt or take other actions which would intensify the risks discussed above.

Despite our current consolidated debt levels, subject to certain conditions and limitations in the indentures related to the 2023 Notes and the 2025 Notes, the Highbridge Loan Agreement and the ~~Solar Loan~~Exchange Agreement, we may be able to incur substantial additional debt in the future, some of which may be secured debt. We may not be subject to any restrictions on incurrence of additional indebtedness under the terms of any future indebtedness. If new debt is added to our current debt levels, the related risks that we and they now face could intensify.

The issuance of additional stock in connection with financings, acquisitions, investments, our stock incentive plan, upon the conversion of our convertible senior subordinated notes or otherwise will dilute our existing stockholders.

Our certificate of incorporation authorizes us to issue up to 450,000,000 shares of common stock and up to 5,000,000 shares of preferred stock with such rights and preferences as may be determined by our board of directors. Subject to compliance with applicable rules and regulations, we may issue our shares of common stock, including by conversion of our convertible notes, in certain circumstances, in connection with a financing, acquisition, investment, our equity incentive plans or otherwise. Any such issuance could result in substantial dilution to our existing stockholders and cause the trading price of our common stock to decline.

We may not be entitled to forgiveness of our recently received PPP Loan, and our application for the PPP Loan could in the future be determined to have been impermissible or could result in damage to our reputation.

On April 22, 2020 we received proceeds of $5.8 million from a loan under the Paycheck Protection Program of the CARES Act, a portion of which may be forgiven, which we intend to use to retain current employees, maintain payroll and make lease and utility payments. The PPP Loan matures on April 21, 2022 and bears annual interest at a rate of 1.0%. Commencing November 21, 2020, we are required to pay the lender equal monthly payments of principal and interest as required to fully amortize by April 21, 2022 any principal amount outstanding on the PPP Loan as of October 21, 2020. A portion of the PPP Loan may be forgiven by the SBA upon our application beginning 60 days but not later than 120 days after loan approval and upon documentation of expenditures in accordance with the SBA requirements. Under the CARES Act, loan forgiveness is available for the sum of documented payroll costs, covered rent payments, covered mortgage interest and covered utilities during the eight week period beginning on the date of loan approval. Not more than 25% of the forgiven amount may be for non-payroll costs. The amount of the PPP Loan eligible to be forgiven is limited because of certain headcount reductions that we implemented in March 2020 and will be reduced if our full-time headcount declines further, or if salaries and wages for employees with salaries of $100,000 or less annually are reduced by more than 25%. We will be required to repay any portion of the outstanding principal that is not forgiven, along with accrued interest, in accordance with the amortization schedule described above, and we cannot provide any assurance that we will be eligible for loan forgiveness, that we will ultimately apply for forgiveness, or that any amount of the PPP Loan will ultimately be forgiven by the SBA. Furthermore, on April 28, 2020, the Secretary of the U.S. Department of the Treasury stated that the SBA will perform a full review of any PPP loan over $2.0 million before forgiving the loan.

Table of Contents

In order to apply for the PPP Loan, we were required to certify, among other things, that the current economic uncertainty made the PPP Loan request necessary to support our ongoing operations. We made this certification in good faith after analyzing, among other things, our financial situation and access to alternative forms of capital, and believe that we satisfied all eligibility criteria for the PPP Loan, and that our receipt of the PPP Loan is consistent with the broad objectives of the Paycheck Protection Program of the CARES Act. The certification described above does not contain any objective criteria and is subject to interpretation. On April 23, 2020, the SBA issued guidance stating that it is unlikely that a public company with substantial market value and access to capital markets will be able to make the required certification in good faith. Subsequently, on April 29, 2020 the SBA issued guidance that it will review all PPP loans of more than $2 million, following the lender’s submission of the borrower’s loan forgiveness application. The lack of clarity regarding loan eligibility under the Paycheck Protection Program has resulted in significant media coverage and controversy with respect to public companies applying for and receiving loans. If, despite our good-faith belief that given our Company's circumstances we satisfied all eligible requirements for the PPP Loan, we are later determined to have violated any of the laws or governmental regulations that apply to us in connection with the PPP Loan, such as the False Claims Act, or it is otherwise determined that we were ineligible to receive the PPP Loan, we may be subject to penalties, including significant civil, criminal and administrative penalties and could be required to repay the PPP Loan in its entirety. In addition, receipt of a PPP Loan may result in adverse publicity and damage to reputation, and a review or audit by the SBA or other government entity or claims under the False Claims Act could consume significant financial and management resources. Should we be audited or reviewed by federal or state regulatory authorities as a result of filing an application for forgiveness of the PPP Loan or otherwise, such audit or review could result in the diversion of management’s time and attention and legal and reputational costs. If we were to be audited or reviewed and receive an adverse determination or finding in such audit or review, we could be required to return the full amount of the PPP Loan. Any of these events could have a material adverse effect on our business, results of operations and financial condition.

ITEM 2: Unregistered Sales of Equity and Securities and Use of Proceeds

Not applicable.

~~Table of Contents~~

ITEM 3: Defaults Upon Senior Securities

Not applicable.

ITEM 4: Mine Safety Disclosures

Not applicable.

ITEM 5: Other Information

None.

Table of Contents

ITEM 6: Exhibits

The exhibits listed on the Exhibit Index hereto are filed or incorporated by reference (as stated therein) as part of this Quarterly Report on Form 10-Q.


Exhibit No.		Document

3.1		Amended and Restated Certificate of Incorporation of Senseonics Holdings, Inc. (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-37717), filed with the Commission on March 23, 2016).

3.2		Amended and Restated Bylaws of Senseonics Holdings, Inc. (incorporated herein by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K (File No. 001-37717), filed with the Commission on March 23, 2016).

3.3		Certificate of Amendment to Amended and Restated Certificate of Incorporation of Senseonics Holdings, Inc. (incorporated herein by reference to Exhibit 3.3 to the Registrant’s Quarterly Report on Form 10-Q for the Quarter ended June 30, 2018 (File No. 001-37717), filed with the Commission on August 8, 2018).

~~10.1 +~~		Senseonics Holdings, Inc. Inducement Plan (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No. 001-37717), filed with the Commission on June 5, 2019).

~~10.2+~~		Form of Stock Option Grant Notice and Stock Option Agreement used in connection with the Senseonics Holdings, Inc. Inducement Plan (incorporated herein by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K (File No. 001-37717), filed with the Commission on June 5, 2019).

31.1*		Certification of Principal Executive Officer under Section 302 of the Sarbanes-Oxley Act.

31.2*		Certification of Principal Financial Officer under Section 302 of the Sarbanes-Oxley Act.

32.1**		Certifications of Principal Executive Officer and Principal Financial Officer under Section 906 of the Sarbanes-Oxley Act.

101.INS*		XBRL Instance Document

101.SCH*		XBRL Taxonomy Extension Schema Document

101.CAL*		XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF*		XBRL Taxonomy Extension Definition Linkbase Document

101.LAB*		XBRL Taxonomy Extension Label Linkbase Document

101.PRE*		XBRL Taxonomy Extension Presentation Linkbase Document

~~+Indicates management contract or compensatory plan.~~*

*Filed herewith.

**These certifications are being furnished solely to accompany this quarterly report pursuant to 18 U.S.C. Section 1350, and are not being filed for purposes of Section 18 of the Exchange Act and are not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

~~Table of Contents~~

4041

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	SENSEONICS HOLDINGS, INC.


Date: ~~August 7, 2019~~June 9, 2020	By:	/s/ ~~Jon Isaacson~~Nick B. Tressler
		~~Jon Isaacson~~Nick B. Tressler
		Chief Financial Officer
		(Principal Financial Officer)

4142


	January 1, 2019				January 1, 2019
	Prior to ASC
��	842 Adoption		ASC 842 Adoption		As Adjusted
Consolidated Balance Sheet Data (in thousands)
Operating lease assets (1)	$	—	$	2,235	$	2,235
Deferred rent non-current (2)	$	84	$	(84)	$	—
Operating lease liabilities (3)	$	—	$	417	$	417
Non-current operating lease liabilities (3)	$	—	$	1,902	$	1,902



Operating Lease Assets and Liabilities	Balance Sheet Classification	Amount
Assets
Operating lease ROU assets	Deposits and other assets	$	2,025
Liabilities
Current operating lease liabilities	Accrued expenses and other current liabilities	$	445
Non-current operating lease liabilities	Other non-current liabilities		1,674
Total operating lease liabilities		$	2,119


2019 (remaining six months)	$	309
2020		629
2021		648
2022		668
2023		282
Total		2,536
Present value adjustment		(417)
Present value of lease liabilities	$	2,119


2019 (remaining six months)	$	5,000
2020		5,000
2021		—
2022		—
2023		52,700
Total	$	62,700